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Background: Solid organ transplant recipients require lifelong immunosuppressive therapy in 
order to prevent graft rejection. Unfortunately, these multiple-drug regimens are associated with 
frequent adverse effects that can negatively impact quality of life (QoL), cause interruptions in 
treatment, and may even contribute to treatment failure (i.e., graft rejection).     
Objectives:  To develop and pilot test a survey that characterizes patient perceptions of adverse 
symptoms of immunosuppressants (ASI), QoL, and medication adherence in a population of 
patients who have received a solid organ transplant.   
Methods: A literature review was undertaken to identify tools assessing patient symptom 
experience, QoL, and adherence in transplant recipients.  A single questionnaire was developed 
to assess all of these domains.  On completion of the survey development phase, the tool was 
piloted electronically to all adult transplant recipient members of the Canadian Transplant 
Association. Questionnaires were interpreted using descriptive analysis and frequencies, and 
respondent’s comments were qualitatively assessed using thematic analysis. Feasibility was 
assessed by response rate, patient’s feedback and missing data. 
Results: The literature search identified three tools that were incorporated into the questionnaire: 
the Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD), the 
Short Form- 12 (SF- 12), and the Basel Assessment of Adherence to Immunosuppressive 
Medications Scale (BAASIS) to measure symptom experience, QoL, and nonadherence to 
immunosuppressive medications, respectively.  The questionnaire was distributed to 249 solid 
organ transplant recipients and achieved a 51% response rate (n=127). Mean age of survey 
respondents was 55.5 ±13.2 years, most had good allograft function, few co-morbidities, and 
reported a similar QoL to that of the general public. More than half of the respondents (61%) 
received their transplant over 6 years ago, and respondents reported a median of 19 different 
adverse symptoms (IQR 12- 27). The most prevalent symptoms for both men and women were 
tiredness, flatulence, and lack of energy (reported at an incidence of 84%, 82% and 70% for 
women and 80%, 76%, and 66% for men, respectively), while the most distressing symptoms 
were tiredness, flatulence, and sleeplessness (mean 2.2, 2.2 and 2.1 on a scale of 0 to 4, 
respectively) in men and joint pain, diarrhea, and lack of energy in women (mean 2.4, 2.4, and 
2.3 on a scale of 0 to 4, respectively).  Nonadherence to immunosuppressive medications was 
reported by 29-50% of respondents. 
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Conclusion: It is feasible to assess symptom experience, QoL and nonadherence to 
immunosuppressive medications using a single tool in transplant recipients. Despite the high 
prevalence of adverse symptoms, QoL remained high in members of the Canadian Transplant 
Association. Wider application of this tool will determine if the findings from this study sample 
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CHAPTER 1: INTRODUCTION 
Solid organ transplantation is the transfer of human organs from a donor to a recipient 
with the aim of restoring function in the body. This revolutionary procedure has become the 
treatment option of choice for patients with kidney failure, and a lifesaving procedure for 
patients with other types of end-stage organ failure, such as heart, lung or liver failure.  
One of the key issues in the field of transplantation is the prevention and management of 
organ rejection, which occurs when the recipient’s immune system recognizes the transplanted 
organ as foreign. To prevent rejection, transplant recipients must take a complex regimen of 
immunosuppressive medications.1 Unfortunately, these medications can cause adverse effects 
(such as hypertension, infection, diabetes and osteoporosis) as well as adverse symptoms (such 
as weight gain, increased hair growth and lack of energy).2-7 Adverse symptoms have not 
garnered as much attention in transplant literature, likely because they may not be perceived to 
be as serious, or to be a direct cause of morbidity or mortality. Nevertheless, adverse symptoms 
can cause significant patient distress, which may impact both quality of life and medication 
adherence. Further studies are warranted to explore the patient perspective on these adverse 
symptoms, and to determine the inter-relation between the three areas of symptom experience, 





CHAPTER 2: LITERATURE REVIEW 
2.1 Background 
Organ failure and the need for transplantation are becoming increasingly common in 
Canada. According to the Canadian Organ Replacement Registry report of 2014, approximately 
2456 solid organ transplants were conducted in that year. Of these, there were 1430 kidney, 537 
liver, 226 lung, 161 heart and 79 pancreas transplants.8 Unfortunately, around 4500 patients are 
still waiting for appropriate donors and 278 people died on the transplant waitlist.8 These 
statistics are particularly alarming, since transplantation may be the only option for survival in 
some individuals with organ failure.9 
Solid organ transplantation was first performed in the 1960’s.10 Although surgery 
provided an option for organ failure, the length of patient survival ranged between a few minutes 
to several months. Unfortunately, the transplanted organ was often rejected by the body, leading 
to a loss of function and high risk of death.  
The human immune system is extremely complex and several pathological mechanisms 
can contribute to organ transplant rejection. Rejection may be classified according to the timing 
at which it occurs in relation to the transplant surgery. If rejection occurs within minutes after the 
transplant it is described as hyperacute rejection. Rejection occurring within days to three months 
of the transplant is considered acute rejection, and rejection occurring months to years post-
transplant is considered chronic rejection. Rejection may be also classified according to 
histology analyses (cellular-interstitial, vascular, and antibody-endothelial); the severity and the 
extent of histologic inflammation and injury. It was not until the advent of the 
immunosuppressive medication cyclosporine in the late 1970’s, however, that the problem of 
organ rejection became more manageable.11  
It is now realized that a combination of immunosuppressive medications is required to 
achieve acceptable outcomes in solid organ transplantation. A study of the United Network for 
Organ Sharing (UNOS) registry in the United States analyzed renal transplant data between the 
years of 1988 to 1996. The use of maintenance immunosuppressive therapy, consisting of a 
combination of corticosteroids along with a calcineurin inhibitor (either cyclosporine or 
tacrolimus), and an antiproliferative agent, resulted in a one-year graft survival rate of 
approximately 80% -90%.12 
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Immunosuppressive protocols may vary, but in general, they are comprised of the 
following phases. 
1) Induction phase: Peri-operatively, a short course of a potent immunosuppressive is given 
parentally to the patient to reduce the risks of acute early rejection and allow for the 
minimization of agents used in the maintenance phase. Examples of immunosuppressive 
agents used in this phase include polyclonal antibodies such as antithymocyte globulin; or 
monoclonal antibodies such as basiliximab, or alemtuzumab; and corticosteroids.13 
2) Maintenance phase: Transplant recipients are required to take a combination of 
immunosuppressive medications for the life of the graft. These medications, which are 
used to minimize the incidence of acute and chronic organ transplant rejection, include 
the calcineurin inhibitors (cyclosporine, tacrolimus), m-tor inhibitors (sirolimus, 
everolimus), antimetabolites (mycophenolic acid derivatives, azathioprine), and 
corticosteroids. 13 
In the event of a rejection episode, additional medications are required to minimize graft 
injury. Agents used may include corticosteroids; polyclonal antibodies such as antithymocyte 
globulin; and monoclonal antibodies such as alemtuzumab or rituximab; and therapies such as 
intravenous immune globulin and plasmapheresis.  
Immunosuppressive regimens are complex and require constant monitoring to maintain 
the balance between rejection and drug toxicity. While insufficient immunosuppression in a 
transplant recipient can lead to organ rejection, over-immunosuppression may increase the risk 
of infection and risk of malignancy. In addition, these medications can cause a variety of side 
effects and adverse symptoms for the patient.  
There are two major areas of focus in dealing with drug-related side effects. The first 
issue relates to emerging common post-transplant co-morbid conditions, which can be caused or 
exacerbated by immunosuppressive medications. Some examples include hypertension, 
hyperlipidemia, osteoporosis, diabetes, and infections.2-4,7 Secondly, there are numerous adverse 
symptoms experienced by transplant recipients. Examples include trembling hands, diarrhea, 
concentration difficulties, fatigue, headache, muscle weakness, insomnia, and changes in 
physical appearance. While they may not pose a direct risk to physical health, these adverse 
symptom experiences can cause significant distress to the transplant recipient. In addition, they 
may directly or indirectly impact other important outcomes that affect the patient’s overall well-
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being, quality of life, and activities of daily living. These factors may ultimately influence the 
patient’s motivation to consistently take the medications as prescribed.14-16 While much attention 
has been given to the toxicities and co-morbid illnesses associated with immunosuppressive 
medications, less is known about the overall experiences of transplant patients regarding the 
adverse symptoms of immunosuppression. 
In recent years, however, research has expanded beyond graft rejection and toxicities to 
consider the patient experience and patient-reported outcomes. Important measures of the post-
transplant experience include quality of life (QoL), and symptom experience (adverse symptom 
occurrence and severity), which may in turn impact medication adherence.16,17 To understand the 
interrelation of these three concepts we need to understand their definition. 
Quality of life is defined by the World Health Organization as “the personal perception 
of an individual of his situation in life, within the cultural context and values in which he lives, 
and in relation to his objectives, expectations, values and interests”.18 In related literature, 
measurement of QoL has been expanded into two aspects. The objective element is based on 
clinical observations, tests and information whereas the subjective element consists of the 
patient’s perception of well-being, according to his/her own standards. The patient’s subjective 
feelings have been shown to be a crucial factor in adherence to prescribed treatment,19-21 and 
may highlight the importance of symptoms that clinicians may overlook or underestimate the 
frequency and influence of on the patient’s daily activities.6 Other aspects related to quality of 
life include symptom occurrence and distress. Symptom occurrence describes the prevalence, 
intensity, and the duration for which a symptom continues to exist, while distress refers to the 
difficulty that it imparts on the patient to carry on with their daily routine.22  
Nonadherence has been defined as a “deviation from the prescribed medication regimen 
sufficient to adversely influence the regimen’s intended effect”, however other groups have used 
different definitions.23 A systematic review of European and North American studies examined 
nonadherence to immunosuppressive medications among solid organ transplant recipients 
between 1981 and 2005. This study concluded that nonadherence rates vary between 7/100 
cases/year for liver transplant recipients, to as high as 36/100 cases/year for kidney transplant 
recipients.24 The measures for nonadherence varied across studies. Some researchers measured 
adherence according to a specific level of immunosuppressive medications present in blood 
samples, while others relied on refill rates, or the percentage of medication removed from an 
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electronic pill bottle. Other researchers yet relied on patient self-reporting. Despite differences in 
definitions and metrics, it is clear that non-adherence represents a major problem in solid organ 
transplantation and is a leading cause of poor post-transplant outcomes. Of further importance, 
rejections caused by nonadherence can negatively impact graft survival and mortality. The 
previously described systematic review of nonadherence studies showed that a median of 36% 
graft losses and a median of 14% graft failures were associated with nonadherence.24 
In a study of 101 heart transplant recipients, nonadherent participants (n=17) experienced 
10% more late acute rejections and 12% more re-transplantations compared to adherent 
participants (n=84) 25. Adherence was measured for cyclosporine using electronic pill bottles 
(Medication Event Monitoring System or MEMS). Patients were considered nonadherent if they 
missed taking their medication within a three hour frame in the morning and evening.25 
Quality of life, symptom experience and medication adherence seem to be closely related. 
Examining the relationship between adherence and quality of life was the objective of two 
studies. The first involved 230 Persian renal transplant recipients, in which a significant 
correlation was reported between adherence and quality of life scores.26 Another study of 25 
adolescent liver transplant recipients reported a significantly lower QoL for the nonadherent 
cohort (p=0.001).27 
Prevalence and intensity of adverse symptoms may collectively contribute to the 
deterioration in QoL. Consistent struggles with day-to-day activities may affect patient 
commitment to abide to the prescribed medication regimen, especially for medications perceived 
to be the cause of these adverse symptoms.28,29 
To date, most studies have gathered information on one or two domains of symptom 
experience, patient QoL and adherence. Moreover, several studies have examined symptom 
experience in populations with only one type of organ transplant.  For instance, one study 
investigated symptom experience in a cohort of patients with heart transplants (n=261).30 
Tiredness, lack of energy, and nervousness were found to be the most common symptoms, noted 
in 89%, 80% and 75% of patients, respectively. The most distressful symptoms, however, were 
found to be erectile dysfunction in men (23%), a decreased interest in sex (both genders-16%), 
and muscle weakness in men (16%).30  
In a cohort of lung transplant recipients (n=85), researchers compared pre- and post-
transplant symptom experience to determine the most frequent and distressing adverse 
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symptoms. Prior to transplantation the main adverse symptom experienced was dyspnea, while 
post-transplant the most frequent symptoms included gastrointestinal problems and neurological 
symptoms, such as tremors.31 
A study of patients with kidney transplants compared symptom experience between 
genders.14 In this study symptoms were classified into low occurrence/low distress, high 
occurrence/low distress, low occurrence/high distress, and high occurrence/high distress. The 
most highly occurring and distressful symptoms reported by men (n=207) were tiredness, joint 
pain, and sleeping disturbances. The least frequent, but very distressing symptoms were anxiety, 
mouth infections, and swollen gums. The three most highly occurring and distressful adverse 
symptoms reported by women (n=149) were tiredness, joint pain and brittle skin. The most 
distressing but infrequently occurring symptoms were painful/excessive menstruation, rash and 
mouth infections. The investigators in this study concluded that the most frequently occurring 
symptoms are not necessarily the most distressing.14 
In a study of 123 liver transplant recipients, investigators characterized symptom 
experience using the Modified Transplant Symptom Occurrence and Distress scale (29-item 
version). Liver transplant recipients reported a mean of 16 out of 29 different adverse symptoms 
(55%). Distress due to symptoms was experienced 1669 times out of 1987 reported symptoms 
(84%) and it was significantly higher in women compared to males.16 
One understudied area in transplant literature relates to transplant recipient’s perceptions 
on causality and management of the adverse symptoms they experience. Whether or not a patient 
perceives something to be treatable may influence how the patient perceives QoL. The perceived 
cause of the ASI is important as it may influence adherence to medications. Understanding 
patient attitudes on perceived causes of frequent/troubling symptoms and whether or not they are 
treatable may provide great insight for health care providers, and assist with the development of 
patient centered management plans. 
Other research examining solid organ transplant recipients collectively have explored 
adherence. One study consisting of 565 participants (including kidney 48%, liver 47%, and other 
transplants 5%), examined the effect of urban versus rural residence on self-reported medication 
adherence. This study showed that 58% of the population was adherent (as measured by the 
Immunosuppressant Therapy Adherence Scale (ITAS)), and that there was a significant 
association between living in rural areas and nonadherence.32  
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Most published studies evaluating QoL in solid organ transplantation have been 
conducted in a single organ cohort (heart, kidney, lung, or liver). In a study of 569 heart 
transplant recipients, QoL was measured using the Life Satisfaction Index (LSI) and the 
Transplant Care Index (TCI). Increased QoL scores were significantly associated with age, 
having a spousal relationship, and having access to a heart specialist as a primary care provider.33 
Somewhat surprisingly, in a cohort of lung transplant recipients (n=17) QoL was relatively 
comparable to the general population.34 However, in a study of adolescent liver transplant 
recipients (n=55), QoL was decreased compared to the general population.35 A systematic review 
on this topic described some of these measures that have been used in kidney transplant 
recipients, including the Short Form-36 (SF-36), Kidney Transplant Questionnaire (KTQ), and 
the Kidney Disease Quality of Life Instrument (KDQoL).36 Another recent systematic review 
identified six generic QoL measures, two disease specific measures, and 12 symptom specific 
tools. 37 
One study simultaneously examined symptom experience, QoL and adherence in an 
adolescent renal transplant population. The most frequent symptoms included fatigue, headache, 
and pimples, while and the most distressing symptoms included moon face, anxiety, and joint 
pain.15 QoL was found to be comparable to the non-transplant population, but nonadherence was 
found in 78% of the cohort. This study, which consisted of only 23 patients, was not designed to 
study the interrelation between symptom experience, QoL and adherence. To our knowledge no 
study has contrasted measures of all three domains in any solid organ transplant population.  
Patient-reported outcomes are becoming increasingly recognized as important indicators 
of the impact of disease or treatment strategy on the patient. Patient perceptions and patient-
reported outcomes provide a clear picture about the patient’s conditions without any external 
interpretation. Understanding transplant recipient perceptions on their symptom experience, QoL 
and adherence to immunosuppressive medications may provide health care providers with tools 
to help facilitate transplant recipients cope with challenges of daily living, and to engage 
transplant recipients in positive behaviors and self-efficacy. This type of research has become 
more widely recognized as important, as health-care systems strive to become more patient-
centered.  
While the value of assessing patient perceptions should be recognized on its own merit, 
this project is part of a much larger initiative. Optimal management of adverse symptoms from 
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immunosuppressive medications has not been clearly defined. To address this, a working group 
consisting of pharmacists and physicians members of the Canadian Society of Transplant (CST) 
has been established to develop leading practice recommendations on the most effective 
management of these adverse symptoms.  The results of this project will serve to inform as the 
foundation for this larger research initiative.    
The purpose of this project is to develop and test a patient survey to characterize the 
symptom experience, QoL and adherence to immunosuppressive medications in solid organ 























CHAPTER 3: STUDY OBJECTIVES 
Objective 1: Identify and critically evaluate existing survey tools for assessing adverse 
symptoms of immunosuppression (ASI), quality of life (QoL), and adherence in transplant 
recipients. (Tool identification) 
Objective 2: Develop a survey that gathers information about ASI, QoL, and adherence, as well 
as capturing clinical situation and patient demographics. (Survey Development) 
Objective 3: Pilot the newly developed survey among a sample of individuals associated with 
the Canadian Transplant Association (CTA). (Pilot Survey) 
Objective 4: Perform a descriptive analysis of the results of the electronic survey, and describe 
following results in frequencies and distributions. (Descriptive Analysis) 
 Patient demographics:  
o age, gender, race, education, employment status, household income, marital 
status, province, proximity to transplant center 
 Clinical situation of subjects: 
o  type of transplant, time since transplant, number of visits to transplant center 
per year, immunosuppressive medications, doses per day, number of rejection 
episodes in the past 3 months, other medical conditions 
 Symptom experience: 
o Prevalence of symptoms 
o Distress associated with symptoms 
o Symptom causal attribution (i.e. immunosuppression, other medications, 
medical conditions) 
o Self-perceived treatability of symptoms 
 Adherence: 
o Overall adherence 
o Implementation and discontinuation 
 Quality of Life: 
o Physical component summary 
o Mental component summary 
Objective 5: Assess strengths and limitations of the survey tool, and feasibility for a multicenter 
study. (Assess Feasibility) 
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 Response rate 
 Time required to complete survey  
 Patient feedback 
 Missingness of data 
The methods and results section of this report will be organized according to the aforementioned 




CHAPTER 4: METHODS 
4.1 Ethical Consideration 
Ethics approval for this project was obtained from the University of Saskatchewan 
Advisory Committee on Ethics in Behavioral Science on January 6, 2015. (Certificate of 
approval number 14-444). 
4.2 Objective 1: Tool Identification  
A comprehensive literature search was undertaken to identify existing validated 
questionnaires relating to symptom experience, quality of life and nonadherence to 
immunosuppressive medications. Quantitative tools that measured QoL, symptom experience or 
adherence in solid organ transplant recipients, and were published in English, were considered 
for review. Review articles, studies that used qualitative measures, studies that were specifically 
designed for use in a certain ethnic group, and studies that were not in English were excluded. A 
medical librarian provided guidance on the search strategy for this stage of the project. Three 
databases were searched, including Medline via Ovid SP, Psychinfo via Ovid SP, and EMBASE 
via Ovid SP. For the quality of life search, the Cumulative Index of Nursing and Allied Health 
Literature (CINAHL) (1969 through 2014) database was also included, since this resource has 
been known to index articles pertaining to this topic. 
4.2.1 Quality of Life 
The following search terms were used for the QoL literature search: [(Transplantation. 
mp.) and (exp Immunosuppressive Agents/ae [Adverse Effects] mp.) and (exp Quality of Life)] 
in Medline via Ovid SP; [(exp Organ Transplantation) and (exp Immunosuppressive Agent) and 
(exp Quality of Life)] in EMBASE via Ovid SP; [(exp “Side Effects (Drug)” / or 
Immunosuppressants. mp.) and (exp Quality of Life) and (Transplantation. mp.)] in Psychinfo 
via Ovid SP; [(MH “Immunosuppressive Agents+”) ̏ and (MH “Quality of Life”) and (MH 
“Organ Transplantation”) or (MH “Heart Transplantation+”) or (MH “Kidney 
Transplantation+”) or (MH “Liver Transplantation”) or (MH “Lung Transplantation+”) or (MH 
“Pancreas Transplantation+”)] in the Cumulative Index of Nursing and Allied Health Literature 
(CINAHL). 
4.2.2 Symptom Experience 
The literature search for tools to measure symptom experience in Medline via Ovid SP, 
EMBASE via Ovid SP, and Psychinfo via Ovid SP included the terms (organ transplantation/or 
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transplantation/or exp heart transplantation/or exp kidney transplantation/or exp liver 
transplantation/or exp lung transplantation/or exp pancreas transplantation/or exp spleen 
transplantation) and (exp immunosuppressive agent/) and ((symptom*adj4 (distress or 
experience*or occur*)).mp. [mp - title, abstract, original title, name of substance word, subject 
heading, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier]. 
4.2.3 Medication Adherence 
The medication adherence search in the three databases (Medline via Ovid SP, EMBASE 
via Ovid SP, and Psychinfo via Ovid SP) consisted of the terms: (organ transplantation/or 
transplantation/or exp heart transplantation/or exp kidney transplantation/or exp liver 
transplantation or exp lung transplantation/or exp pancreas transplantation/or exp spleen 
transplantation) and (medication compliance/or exp patient compliance) and (exp 
immunosuppressive agent/).  
4.3 Objective 2: Survey Development 
It was determined that the survey would contain five sections: 1) demographic and 
clinical characteristics; 2) symptom experience; 3) quality of life; 4) adherence to 
immunosuppressive medications; and 5) comments.  
The demographic questions section was included to assist in characterizing the 
population. A series of relevant demographic questions were drafted from the research team, and 
an additional expert in transplantation was consulted to review the questions for relevance in this 
population. 
Tools to assess symptom experience, quality of life, as well as adherence, were generated 
from the literature search in objective one. Preference was given to instruments with proven 
validity in transplant populations, and instruments that were used to study different types of solid 
organ transplants (versus just one specific organ group), were comprehensive in quantifying 
symptom experience, QoL, or adherence to immunosuppressive medications and concise in 
nature. With respect to self-reported adherence, we aimed to identify a tool that accounted for 
both the number of doses taken as well as the timing of administration of immunosuppressive 
medications.  
 For symptom experience, there was the desire to comprehensively cover the occurrence 
and distress of the adverse symptoms, as well as including as many adverse symptoms as 
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possible. We also aimed to assess the patient’s perception of causal attribution and treatability of 
the adverse symptoms experienced. Adapting causal attribution and treatability questions into the 
selected symptom experience tool was preferred rather than adding another tool, to minimize 
survey burden. With respect to quality of life and adherence, concise tools were also given 
preference since the patient experience section alone would be lengthy. 
As is common practice in survey design,38 an open-text comment box was added at the 
end of the questionnaire to collect additional details and feedback from the respondents. These 
comments were potentially important in this study since one of the objectives was to assess the 
feasibility of a future multi-center study.  
4.4 Objective 3: Pilot Survey 
4.4.1 Study Population 
The questionnaire was sent to patients with a solid organ transplant who were members 
of the Canadian Transplant Association (CTA). The CTA is a national charitable organization 
with a mandate of raising awareness of organ and tissue donations.39 Their membership consists 
of donor families, living donors and their relatives and friends, health care professionals, and 
approximately 249 transplant recipients. The transplant cohort includes recipients who have 
undergone a solid organ, tissue, or stem cell transplant.  This group includes a diversity of solid 
organ transplant types (e.g. kidney, liver, multi-organ, etc.) widely geographically distributed 
across the country, which was ideal for the purposes of this pilot study.  Correspondence with 
CTA executives revealed that the CTA members are active users of the association’s website, 
and emails are the preferred form of communication, hence the link to the survey was distributed 
by email. 
4.4.2 Questionnaire Distribution & Data Collection 
An invitation to complete a questionnaire was emailed to the CTA membership list by the 
website administrator. Filter questions were included to specifically identify participants who 
have received a solid organ transplant, and to exclude pediatric patients. To minimize the survey 
length, and avoid unnecessary complexity, a survey platform with options for skipping questions 
and branching questions was needed. Various survey platforms were tested to assess their 
suitability for this questionnaire. The Research Electronic Data Capture (REDCap) survey tool 
hosted through the University of Saskatchewan was deemed the most appropriate platform for 
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this study.40 In addition to meeting the requirements of unlimited skip logic and branching 
options, technical support for this software was easily accessible on campus. 
The time required to fill out the survey was estimated to be between 30 and 45 minutes 
according to feedback after testing on laypersons. Although this may be viewed as lengthy, by 
way of this pilot we hoped to determine the appropriate balance between keeping the survey 
concise and covering the research topic in a comprehensive manner. In a systematic review of 
electronic surveys, Sheehan and colleagues analyzed 31 studies conducted between the years 
1986-2000, resulting in an average response rate of 37%.41 Assuming a high degree of patient 
buy-in to a topic likely of importance to them, we aimed to achieve a response rate of 40%. 
Response rate is essential to the success of any survey. To encourage a high response 
rates, the Dillman Tailored Design method was utilized.42 This method recommends 
communicating with the study population multiple times. An invitation is initially sent that 
explains the expected impact of the study and the importance of responses, and reminders are 
sent to non-responders to encourage participation. The use of concise and simple wording is 
recommended in all communications. As recommended by Dillman and other survey experts,42-44 
we planned to send an advance email approximately one week prior to the survey distribution. 
Two reminder emails were also to be sent to potential participants consecutively, approximately 
one week after the email containing the actual survey link was received.  
Participants were given the option to receive a $ 5 Tim Horton gift card as compensation 
for their time to fill the survey. If the respondent opted to accept the incentive, they were 
redirected to a separate survey to provide their contact details.  
In order to preserve the anonymity of the respondents, the CTA executive was 
responsible for distributing the surveys to their members. In a deviation from accepted survey 
practices, the CTA executive claimed that sending too many emails in a short time frame could 
burden the members and provoke them to unsubscribe from the email distribution list. The 
emails were therefore consolidated and the interval between the emails was extended. Data 
collection occurred between April 20th, 2015 and May 26th, 2015 according to the following 
schedule: 
 April 20th – Initial email sent to the entire mailing list of the CTA, including a cover letter 
and a link to the survey (Appendix 1). 
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 April 27th – First reminder email sent to the entire mailing list of the CTA, which 
contained a link to the survey (Appendix 2). 
 May 20th – Second reminder email sent to the entire mailing list of the CTA, which 
contained the survey link (Appendix 3). 
 May 26th – Data collection concluded. 
Each questionnaire had a unique identification number, and all of the responses were saved on a 
password secured laptop that was maintained by the research team. 
4.5 Objective 4: Descriptive Analysis 
Data was directly imported from the REDCap survey platform into the Statistical 
Package for Social Sciences (SPSS 19.0 for Windows®). Statistical tests such as mean, median, 
range, frequency, and standard deviation were used to analyze patient demographics. The 
questionnaire consolidated three previously validated tools, each with a specific recommended 
analysis plan, hence statistical analysis was initially performed on each section separately.  
The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-
R59),45 which was used to measure symptom experience, consisted of a large number of 
questions that are ordinal in nature. For the symptom occurrence questions, the responses were 
stratified according to gender, and the scores were summed and grouped into tertiles (highest, 
medium, lowest prevalence symptoms). Mean scores were calculated for the distress questions, 
which used a numerical Likert scale ranging from ‘not distressing at all (0)’ to ‘terribly 
distressing (4)’. Mean calculations took into account the number of respondents reporting a 
certain value, as well as the distress value they selected (i.e., if two respondents scored 0 and one 
respondent scored 1, the denominator was three since this is the number of respondents that 
answered the distress question). Causal attribution and treatability questions were reported as the 
proportion of respondents who answered with ‘strongly agree’ or ‘agree’ to each question on a 
scale of ‘strongly agree’ to ‘strongly disagree’.  
The QoL assessment was conducted with the Short Form-12v2 (SF-12®). This analysis 
was carried out using the Quality Metric Health Outcomes® Scoring Software 4.5, which 
generated reports comparing the physical and mental health scores of the respondents to general 
populations, and compared eight items: physical functioning, physical role, general health 
perceptions, bodily pain, vitality, social functioning, emotional role and mental health. The 
software translated the values into norm-based values (with 50 equating to the US average ± 
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standard deviation of 10), to provide a better understanding of our sample compared to the 
general population (albeit, not Canadian), taking into consideration age and gender norms.  
The BAASIS© 46 tool measured patients’ implementation and discontinuation phases of 
immunosuppressive medications in the last four weeks across four questions using a 6-point 
Likert scale ranging from ‘never (0)’ to ‘every day (5)’. The implementation phase refers to the 
patient’s ability to take the medications according to the prescribed regimen, at the correct time, 
without missing doses, while the discontinuation phase refers to whether the patient stopped 
taking their medications. A ‘yes’ answer to any of the first three questions indicated an issue in 
implementation, while a ‘yes’ answer to question four indicated a discontinuation of 
immunosuppressive medications. Overall adherence was captured as a dichotomous variable, 
combining answers from both implementation and discontinuation questions. A ‘no’ response on 
all questions (1a, 1b, 2, 3, and 4) indicated overall adherence, while a ‘yes’ response on any of 
the questions (1a, 1b, 2, 3, and 4) was considered non-adherent. Overall adherence was also 
captured as a continuous variable, with respondents reporting adherence to immunosuppressive 
medications over the last 4 weeks on a visual analog scale (VAS), in which higher scores 
represented higher overall adherence. 
4.6 Objective 5: Assess Feasibility  
To assess the feasibility of examining of symptom experience, quality of life and 
nonadherence in a single survey tool, the following aspects were taken into consideration: 
response rate, time required to complete survey, missing data, patient feedback.  
Response rate was calculated by dividing the number of respondents who filled the 
survey completely (demographics and clinical, symptom experience, quality of life and 
adherence to immunosuppressive medications) by the total sample. Patients who did not provide 
a response on all questions were defined as partial responders. The electronic platform did not 
have the capability of capturing the time required to complete the survey, because respondents 
could complete the survey in more than one session (i.e. start the survey, save their answers and 
then restart from where they stopped last time). The research team opted to use this approach 
since they believed it would positively impact on completion rate. Missing data was calculated 
separately for each patient, based on the differing item response characteristics of each survey. 
This approach was necessary since each respondent had a different number of total questions 
(based on immunosuppressive medication choices and symptoms reported). 
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Qualitative patient feedback was also captured to gain insight into the perspectives of 
respondents regarding the survey topic and/or survey itself. Thematic analysis was used to 
identify common themes from patient’s comments.  This involved compiling the responses and 
reviewing the data, labeling or coding the data, identifying initial patterns or themes in the 
responses, reviewing the themes and then defining and naming the themes, and summarizing 




CHAPTER 5: RESULTS 
5.1 Objective 1: Tool Identification  
5.1.1 Symptom Experience 
The systematic literature search for symptom experience generated 348 original articles 
(Figure 1).  Twenty-two articles emerged as relevant, and four separate tools were reviewed. 
Figure 1. Summary of the search strategy to identify articles pertaining to symptom experiences 







 Modified Transplant Symptom Occurrence and Symptom Distress (MTSOSD)  
The MTSOSD scale is a self-administered questionnaire designed to measure symptom 
occurrence rated on a five-point scale from ‘never occurring (0)’ to ‘always occurring (4)’, and 
symptom distress from ‘not at all distressing (0)’ to ‘extremely distressing (4)’. The original tool 
was designed to be used in heart transplant recipients and assessed the occurrence and distress of 
27 immunosuppression adverse symptoms on a Likert scale.47 The questionnaire has since been 
modified to include a total of 59 symptoms, to be inclusive of other types of organ transplants, 
and newer immunosuppressive medications. 
A study aimed at updating and validating the 59 items in the MTSOSD scale was carried 
out in 24 renal and 84 lung transplant patients. Pilot testing was conducted on the renal transplant 
recipients to measure the clarity of the questions and the participants’ comprehension of the 
questions. The questionnaire was modified according to this feedback and tested again in the 
lung transplant group. Discriminant validity was tested by comparing symptom experience 
between men and women, and also between patients with and without depressive symptoms. 
Women reported a significantly higher level of symptom distress compared to men (p = 0.0017), 
and also a tendency towards a higher symptom occurrence compared to men. Patients with 
depressive symptoms reported a higher symptom occurrence (p = 0.030) and a higher symptom 
distress (p = 0.006) compared to those with no depressive symptoms.45 
Two other studies aimed to validate the MTSOSD tool. The first study was conducted on 
113 renal transplant recipients in Belgium.48 Content validity was tested by a thorough review of 
the literature, and an experts’ review (consisting of two clinical nurses, two nephrologists, and 
two cardiologists). Construct validity was assessed from transplant literature reporting that 
symptom occurrence and distress are correlated with depression, and that women experience 
more adverse symptoms and distress than men. The results obtained from this study were 
consistent with these assumptions, as both symptom occurrence and distress were correlated with 
depression and symptom distress and depression were correlated using (Spearman coefficient (r 
= 0.32 and r = 0.54; p < 0.001, respectively).  Women expressed higher scores for symptom 
occurrence and distress compared to men (p < 0.001). Finally, discriminant validity was 
evaluated by comparing the transplant recipients to a healthy control group, in which the 
transplant recipients reported significantly higher scores for symptom occurrence and symptom 
distress (p < 0.00001).48  
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The second validation study adapted a translated version of the questionnaire in Turkish 
to 180 liver and kidney transplant recipients.49 The content validity index showed an ideal score 
of 1.0 according to 13 expert reviewers, indicating that it accurately measures knowledge of 
adverse symptoms occurrence and distress. Construct validity was confirmed in 30 liver 
transplant recipients, where women reported a higher symptom frequency and more symptom 
distress than men (p < 0.01). Higher symptom occurrence and more distress also occurred in 
participants who reported high depressive values compared to participants who reported low 
depressive values (p < 0.001). The Spearman-Brown coefficient was 0.991 for symptom 
occurrence and 0.992 for symptom distress, which suggests that occurrence and distress were 
correlated.49 
The MTSOSD has been used in several studies in kidney and liver transplant populations 
to assess relationships between symptom experience and adherence. A study in Taiwan 
investigated the relationship between symptom experience and side effects on 
immunosuppressive medications, and effect on treatment adherence among 412 kidney 
transplant recipients.50 In another study conducted in Belgium, the MTSOSD was used to 
evaluate quality of life, treatment adherence, and patient and parent perceptions of adverse 
symptoms in 23 adolescent renal transplant recipients.15 The MTSOSD scale was also used to 
assess symptom experience, and to study the relationship between symptom experience and 
immunosuppressive medication nonadherence in 123 liver adult transplant recipients,16 and 239 
kidney transplant recipients.51 A final study explored adverse effects of immunosuppressive 
medication and their relation to symptom experience in 356 kidney transplant recipients on 
maintenance immunosuppressive therapy.14  
Heart transplant studies have used the MTSOSD as well. The MTSOSD assessed 
symptom experience related to adverse symptoms of immunosuppressive medications in 105 
such patients, finding that hair growth was the most prevalent symptom in both women and 
men.47 In another study of 261 German heart transplant recipients, the most prevalent symptoms 
were tiredness, lack of energy, and nervousness.30  
 The MTSOSD tool has also been used to study the effect of specific immunosuppressive 
agents on symptom experience. In a study of 666 kidney transplant recipients, the interrelation 
between kidney function, quality of life, and adverse symptoms of immunosuppressive 
medications was investigated, along with the impact of belatacept and cyclosporine. 52  
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 Memphis Survey 
The Memphis Survey was developed and psychometrically validated at the University of 
Tennessee. It consists of 107 items and measures the presence of adverse symptoms of 
immunosuppression and how troubling they are to the individual on a five-point scale from ‘not 
at all (0)’ to ‘all the time or extremely troubling (4)’. The tool was pilot tested for clarity and 
content among 13 kidney transplant recipients.53 Following this, it was tested for internal 
consistency in an American study of heart, kidney, kidney-pancreas and liver transplant 
recipients (n=505) (Cronbach alpha>0.8).54 A third study used the Memphis survey to evaluate 
immunosuppression-related side effects in 722 solid organ transplant recipients (heart, kidney, 
liver, lung, pancreas and intestine) in the United States.55  
 The Symptom Frequency Intensity and Distress scale:  
The original tool was designed in 1978 to assess symptom distress in chronic medical 
conditions. It included 10 symptoms (nausea, mood, appetite, insomnia, pain, mobility, fatigue, 
bowel pattern, concentration and appearance). Fifty-three cancer patients tested the tool and 
showed acceptable consistency (coefficient alpha= 0.82, standardized alpha=0.83).56 The scale 
was subsequently modified in a Swedish study to evaluate health related QoL in 25 stem cell 
transplant recipients.57 The new version includes 25 items and measures symptom frequency on a 
four-point scale from ‘no, not at all (0)’ to ‘yes, very much (3)’. It also measures the intensity 
and the impact of symptoms on daily life (0=no impact to 3=great impact). One question in the 
survey asks the patient to rate perceived general health, using the response scale 0=excellent to 
3=poor.57 The following symptoms are investigated on this questionnaire: nausea, vomiting, 
fever, shivering, cough, pain, breathing, tiredness, dry mouth, sore mouth and throat, changes of 
taste, diarrhea, constipation, skin problems, poor appetite, sleep problems, ambulation problems, 
eye problems, depression, anxiety, difficulties in concentrating, forgetfulness, hair loss, sexual 
problems and change of appearance.  
 The Transplant Symptom Inventory: 
The Transplant Symptom Inventory was developed in the United States to assess patient 
symptoms before and during the first year of transplant and was tested in 85 lung transplant 
recipients.31 Consisting of 64 items, it measures symptom frequency and distress using a 5-point 
Likert scale. Subjects rate how frequently each symptom occurs from ‘never (0)’ to ‘always (4)’, 
and then rate how distressing each symptom is from ‘never (0)’ to ‘extremely (4)’. A committee 
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of five experts (three nurse practitioners and two lung transplant physicians) confirmed content 
validity from previous literature and their clinical experience. Cronbach’s alpha for symptom 
occurrence was 0.912 and 0.962 for symptom distress, indicating excellent internal consistency 
of the questionnaire.31 
Summary: 
Preference was given to validated instruments that assessed as many adverse effects of 
immunosuppressive medications as possible, covered the two dimensions of symptom 
experience (occurrence and distress) and were widely used in transplant populations. The 
MTSOSD-59 version was determined to best match these criteria, and was chosen over the 
Transplant Symptom inventory because it had been used in more organ populations and had 
more studies to support its validity. 
5.1.2 Quality of Life 
The initial search assessing QoL in transplant recipients generated 349 articles.  Of these, 
41 articles containing 21 instruments were identified in the systematic search assessing QoL in 
transplant recipients. Eighteen tools were eliminated due to their specificity and focus on specific 
area/s of QoL rather than a comprehensive tool that measures overall QoL in adult transplant 
recipients (Table 1). 
Table 1. Eliminated quality of life instruments and rationale 
QoL Tools Focus 
The Gastrointestinal Symptom Rating Scale 
(GRSR)  
Gastrointestinal associated common 
symptoms.58-62  
Gastrointestinal Quality of Life Index 
(GIQLI) 
Gastrointestinal specific health related QoL.61,62 
The Brief COPE Different coping dimensions to transplant.63 
The Social Support Scale (SSS) Social support provided to the individual by the 
people in their lives (i.e. family, friend, 
transplant team members).64 The Personal Resource Questionnaire 
(PRQ2000)  
Perceived l vel of social support.63 
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QoL Tools Focus 
The Psychosocial Adjustment to Illness 
Scale (PAIS)  
Additional psychosocial dimensions of health- 
related QoL.65 
The Child Health Questionnaire (CHQ)  Children and young people aged 4-18 years.35 
The Objective Karnofsky Performance 
Status  
Intensity of treatment and ability of the patients 
to take care of themselves.65 
The Baecke Scale  Physical activity at work, during leisure time, 
and sports during leisure time.5 
The Beck Depression Inventory Patients’ depressive symptoms.5,66-69 
Stat and Trait Anxiety Inventories Y1 and 
Y2 (STAI) 
Anxiety.70 
the Psychological General Well-Being 
Index (PGWBI) 
Psychological health and well-being.62,70 
The Life Satisfaction Index (LSI)  General feelings of well-being.33,71,72 
The Perceived Health and Competence scale Perceived self-efficacy relevant to health in 
general.63 
The Quality of Life index tool Kidney 
transplant version 3 
Satisfaction and importance of various domains 
to kidney transplant recipients.64 
The Sickness Impact Profile (SIP) Health problems interference with daily 
activities and behaviours.73 
Nottingham Health Profile scale (NHP) Subjective health status.74 
 
After eliminating the above instruments for the aforementioned reasons, three tools were 
considered: The Short Form 36, the Short Form 12, and the Euroqol. 
 Short Form 36 (SF-36): 
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The SF-36 is one of the most widely used health related QoL scales. It consists of 36 items 
and covers eight subscales, which measure health concepts in the following dimensions: physical 
functioning, physical health, bodily pain, general health, vitality, social functioning, emotional 
and mental health. It has been used in various solid organ transplant populations (lung, kidney, 
heart and liver).5,52,58,65,67-69,75-85 Data from the Medical Outcome Study (MOS)86 were used to 
test the SF-36’s clinical validity. Correlation of clinical tests of validity were compared. Three-
quarters (74%) of patients with serious medical and depression conditions reported their health 
as poor. However, nearly half (44%) of patients with serious medical conditions and 22% of 
patients with minor medical or depressive conditions reported poor health.82 A comparison of the 
SF-36 scores in healthy individuals, and other chronically ill populations is available for many 
countries.86 
 Short Form 12 (SF-12): 
The SF-12 is a validated short version of the SF-36. It consists of two items for each of 
the domains of physical functioning, emotional, general health and mental health, and one item 
for the domains of bodily pain, general health, vitality and social functioning. The eight 
subscales are aggregated into two component summaries, the physical component score (PCS) 
and the mental component summary (MCS). Each domain is scored on a scale of 0 to 100, with 0 
and 100 representing worst and best QoL, respectively.  The SF-12 software compares individual 
scores to the adjusted norm-based values of a US healthy individual (with a score of 50 equating 
to the US average ± standard deviation of 10). Mid point of 50 indicates average health 
comparable to norm values.  
Criterion-related validity was confirmed in a study conducted on 44395 dialysis patients in 
2006, which compared scores of the SF-36 to scores of the SF-12. A high correlation coefficient 
was obtained between the two tools (r=0.94 for PCS and MCS subscales, p<0.0001).87  
The SF-12 has been used in several transplant cohorts. In one study of liver transplant 
recipients (n=126) quality of life was assessed in relation to unemployment,88  while in another 
liver cohort (n=31) quality of life was compared before and after modifying immunosuppressive 
medications (by switching mycophenolate mofetil to enteric coated mycophenolate sodium).60 A 
study of multi-organ transplant recipients (n=722) used SF-12 to compare differences in quality 
of life according to transplanted organ, based on time since transplant and different 
immunosuppressive medication protocols.55 Another study used SF-12 in kidney transplant 
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recipients (n=231) to measure differences in quality of life for patients with different 
immunosuppressive medications (cyclosporine vs. tacrolimus vs. experience with cyclosporine 
and tacrolimus).89 The tool was used in liver transplant recipients (n=36) to evaluate quality of 
life after 20 years or more of transplant).90 
 Euroqol (EQ-5D): 
The EQ-5D consists of two sections. The first section involves five items to assess the 
patient’s level of functioning, while the second is a 20 cm visual analog scale, in which the 
patients are asked to rate their health on the day they are filling out the survey.5,91,92 Validity was 
tested in a random sample (n=1980) of patients obtained from two clinic registries in the UK. 
Those who had a medical problem and/or a chronic disease reported more problems compared to 
a matched healthy sample on all of items on the EQ-5D (ability to visit the doctor clinic, self-
care, main activity, leisure activity, pain/discomfort and depression/anxiety) (p<0.05) indicating 
construct validity. Discriminant validity was examined by comparing the EQ-5D scores to the 
SF-36 scores for the total population. Agreement in scores was noted between the scales, with 
EQ-5D and SF-36 Spearman’s rank correlation coefficient ranging from 0.48-0.6 (p<0.01), It is 
worth mentioning that EQ-5D has been reported to be less sensitive compared to the SF-36 in 
three of the response categories.93 
Summary: 
 Since preference was given to validated and previously used tools in transplant 
populations, this narrowed the choice to SF-36, and SF-12. The SF-12 was determined to be the 
most suitable instrument to be used in this project, primarily due to its brevity. Since QoL was 
only one of three areas to be explored, a brief, yet comprehensive tool was required to keep the 
survey to a reasonable length.87 
5.1.3 Medication Adherence 
Adherence to immunosuppressive medication was the focus of 323 articles. Of these 32 
articles and seven quantitative tools were identified, two tools were eliminated due to their 
specificity for certain populations (pediatrics) and one tools was eliminated as it was written in 
Japanese.  Four tools that were selected for further review were: 
 
 
 Medication Adherence Report Scale (MARS): 
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The MARS consists of two questions reflecting unintentional nonadherence (e.g. forgot 
to take my medications), and three questions on intentional nonadherence (e.g. deliberate 
decision to skip a dose). Questions are rated on a 5-point Likert type scale encompassing 
‘strongly agree to strongly disagree’. MARS was validated in a study of liver transplant 
recipients (n=444) that compared three different measures of nonadherence (immunosuppressive 
medications blood levels, physician reported adherence, and patient self–reported adherence) 
using patient medical charts between the years of 2003 and 2009. Convergent validity was 
evident as physician reported rates of nonadherence were associated with self-reported 
nonadherence (Odds ratio: 2.5, p=0.03), as well as tacrolimus blood levels variations from a 
specified clinical target, which was set to be 100-350 ng/ml for cyclosporine and 6-10 ng/ml for 
tacrolimus (r= 0.43, p=0.03 R2 = 0.015).94 The MARS was also used in a study that aimed to 
explore differences in intentional and nonintentional nonadherence to immunosuppressive 
medications in 218 kidney transplant recipients in London.66  
 Immunosuppressant Therapy Adherence Scale (ITAS): 
The ITAS is a 4-item questionnaire that asks respondents how frequently they behaved in 
terms of forgetfulness, carelessness, and cessation of immunosuppressive medications as a result 
of the adverse symptoms experienced in the previous three months. Answers are rated on a 4-
point Likert-type scale as follows: 3=0% (none of the time), 2=1-20%, 1=21-50%, and 0=greater 
than 50% of the time (very frequent). Scores of ITAS can range from (0) poor adherence to (12) 
perfect adherence.  
Validity of the ITAS was examined in three studies. The first study was conducted by 
Chisholm (the developer of the ITAS scale) in a population of (n=222) kidney transplant 
recipients.95 Self-reported scores were significantly correlated with that of serum creatinine and 
serum concentration of immunosuppressive medications (p<0.01), indicating convergent 
validity. An acceptable internal consistency was also achieved (Cronbach’s alpha=0.81).95 The 
second study involved 137 kidney transplant recipients. The adherence rate (65%) calculated by 
the ITAS was consistent to the adherence rate obtained through refill records (63%), which was 
evidence for convergent validity.96 The third study aimed to evaluate the psychometric properties 
among 141 solid organ transplant recipients. Scores of the ITAS were significantly associated to 
scores from tools used to assess social support and adaptability (r ≥ 0.2, p<0.05), indicating 
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construct validity. Cronbach’s alpha was 0.87 and the Guttman split-half coefficient was 0.9, 
indicating good internal consistency and reliability, respectively.97  
 The ITAS was used to determine adherence in a sample of 556 solid organ transplant 
recipients. In this study of kidney, liver and other transplants, just over half (58%) of the 
population was shown to be adherent to their immunosuppressive medications (ITAS total score 
of 12).32 The tool was also used to assess differences in adherence in kidney transplant recipients 
(n=808) between two immunosuppressant regimens (enteric coated mycophenolate sodium vs. 
mycophenolate mofetil). 98 In a study of 744 kidney transplant recipients, the ITAS was used to 
measure adherence during the first year after transplant. Nonadherence rates peaked at the end of 
the third month and then plateaued for the next nine months.99 A study of 512 kidney transplant 
recipients explored the relationship between adherence to immunosuppressive medications, as 
well as barriers to adherence and life satisfaction. Nonadherent recipients (177/512) scored 
higher on the immunosuppressant therapy barrier scale than adherent recipients (p<0.001).  
Nonadherent patients also had lower life satisfaction scores than the adherent ones (p < 0.001).100 
In a study investigating the relationship between social support and adherence to 
immunosuppressive medications, 81 kidney transplant recipients reported a significant 
correlation between social support and adherence (correlation coefficient=0.214, p<0.05).101 The 
tool was also used to measure differences in adherence to immunosuppressive medications based 
on patient perceptions of benefit, and the impact of those beliefs on symptom experience 
(n=326).102  
 Basel Assessment of Adherence with Immunosuppressive Medication Scale 
(BAASIS): 
There are two versions of the BAASIS. The interview questionnaire is conducted by a health 
care professional, while the paper version of the questionnaire is self-reported by the patient. 
Both versions contain the same questions, with slightly different wording. This scale is 
composed of four items that quantify taking and timing of medication, drug holidays, and dose 
reductions.  
The translated English version of the questionnaire was validated in a study of 100 
kidney transplant patients in Brazil. Cronbach’s alpha indicated an acceptable internal 
consistency of 0.7. A convenience sample of 21 members of the original population was used to 
examine the test-retest reliability, reporting high agreement (95.2%) and a Kappa coefficient of 
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0.88. Revisions recommended by a committee of experts and feedback from a sample of patients 
was used to finalize the tool and assess content validity. The final version of the tool was 
assessed for criterion validity (Spearman’s correlation coefficient 0.65, p<0.001). 103  
The BAASIS was used in a study conducted among different types of solid organ 
transplant recipients (79 heart, 55 liver, 104 lung) in Belgium, to assess self-reported 
immunosuppressive medications nonadherence, along with electronic monitoring and tacrolimus 
blood assays. Interestingly, rates of nonadherence were found to be higher with the self-reported 
measure compared to electronic monitoring and assay values.104 A group of 1505 solid organ 
transplant recipients (kidney, liver, lung and heart) also used the BAASIS to report pre-and post-
transplant nonadherence.105 
A variety of kidney transplant studies have used the BAASIS to assess adherence. It was 
used in a study in the Netherlands to explore the effect of goal cognition, illness and treatment 
perception on adherence 6 months after renal transplant (n=113).106 Another study used the tool 
to compare three different ways of measuring nonadherence (self-report, physicians’ assessment 
and immunosuppressive medications blood levels) in 241 kidney transplant recipients.107 The 
relationship between nonadherence to immunosuppressive medications and patient perceptions 
was explored in another study of 212 kidney recipients. This study showed that recipients who 
believed their medication was important were more adherent with their medications.108 
Nonadherence to immunosuppressive medications and daytime sleepiness were studied in 926 
kidney transplant recipients. A significant association between sleepiness and nonadherence was 
reported (p<0.001).109 Finally, the BAASIS was used in a population of adolescent renal 
transplant recipients (n=62). Approximately two thirds of the population (65%) reported 
nonadherence in the last four weeks of taking immunosuppressive medications.110  
A few studies have also used the BAASIS in heart transplant cohorts. A secondary 
analysis of the BRIGHT study evaluated nonadherence to immunosuppressive medications in 37 
transplant centers in 11 countries (n=902), where respondents reported an overall nonadherence 
of 36%.111 A pilot study of heart transplant recipients (n=50) used the tool to measure 
nonadherence differences after simplifying the medication regimen (twice daily CNI vs. once 
daily modified release tacrolimus). A decrease in nonadherent behavior was associated with 
regimen simplification 112 A follow up study that involved 72 heart transplant recipients showed 
29 
 
similar results. Nonadherence at baseline was 75%, while at eight months it decreased to 40% 
(p<0.0001).113  
 Morisky Medication Adherence Scale (MMAS-4): 
This scale consists of 4 measures of nonadherence: Patients 1) forgot taking their 
immunosuppressive medications, 2) were careless about taking their immunosuppressive 
medications, 3) discontinued immunosuppressive medications due to feeling better, or 4) 
discontinued immunosuppressive medications due to feeling worse. An answer of ‘yes’ to any of 
those items indicates nonadherence.  
Criterion validity of this tool was explored by comparing its results to immunosuppressive 
blood levels variation among 209 renal transplant recipients in China. Adherence scores 
measured by this scale were significantly associated with immunosuppressive medications blood 
levels (p< 0.001) and good internal consistency was reported (Cronbach’s alpha=0.703) .114  
The MMAS-4 was used in three additional studies to assess adherence. In a study of heart 
transplant recipients (n=99), 33% reported nonadherence to immunosuppressive medications.115 
A cohort of kidney transplant recipients (n=312) showed an increase in nonadherence over time 
using the MMAS-4.116 Finally, the MMAS-4 was used in a study of liver transplant recipients 
(n=65) to assess whether adherence varied with two immunosuppressive regimens. 117  
Summary: 
Preference was given to tools that were widely used in transplant literature, assessed 
different areas of nonadherence to immunosuppressive medications (medications intake, 
administration, regularity of drug intake, presence of drug holidays). The BAASIS was chosen 
for this project, as it was the only tool that assessed both taking and timing of 
immunosuppressive medications. 
5.2 Objective 2: Survey Development 
  Five major domains of information were deemed necessary for this questionnaire, 
demographics and clinical characteristics, symptom experience, quality of life, adherence to 
immunosuppressive medications and comments.  Thus, these sections were developed 
independently before merging into one single tool.  
5.2.1 Demographics  
Two filter questions were included to ensure the target population (i.e., adult solid organ 
transplant recipients) was responding to the survey. Standard socioeconomic status questions 
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were included to describe age, gender, ethnicity, education, employment, family income, marital 
status, and province of residence. Transplant specific questions were included to characterize the 
transplant and assess comorbidities and disease stability, such as type and year of transplant, 
medication regimen and frequency, incidence of transplant rejection, other medical conditions 
experienced, and kidney function. 
5.2.2 Symptom Experience  
The MTSOSD-59 version was incorporated into the questionnaire to measure symptom 
experience. This tool measures the frequency and distress of 59 adverse symptoms potentially 
associated with immunosuppressive medications. Female/male versions differ in item nine: 
Painful menstruation/impotence. In addition, a 60th symptom (heartburn) was included, as it was 
identified to be a common adverse symptom in transplant recipients by the research team. At the 
end of the 60th item, respondents were given the option of reporting two additional adverse 
symptoms that they might have experienced that were not included in the questionnaire. 
Each question asked the respondent about the occurrence, the distress, and the perceived 
cause of the adverse effect, including immunosuppressive medications, other medications or 
underlying medical conditions. Respondents were given the choice along a continuum of ‘never’ 
to ‘always’ for symptom occurrence. If they chose anything but never (i.e., occasionally, 
regularly, almost always or always) they would be directed to rate their symptom distress on a 
scale from ‘not distressing at all (0)’ to ‘terribly distressing (4)’. Next, questions were 
specifically asked based on which immunosuppressive medications were reported in the 
demographic section of the questionnaire. For instance, if the respondent chose sirolimus as part 
of their immunosuppressive regimen, they were asked whether they believed sirolimus was 
causing the adverse symptom. Distress, cause, and treatability sequence questions were prompted 
for each adverse symptom. Respondents reported cause and perceived treatability of each 
potential adverse symptom on a Likert scale of ‘strongly agree’ to ‘strongly disagree’.  
5.2.3 Quality of Life 
The SF-12 was compiled into the questionnaire to measure QoL. The SF-12 software 
compares individual scores to the adjusted norm-based values of a US healthy individual (with a 
score of 50 equating to the US average ± standard deviation of 10). Physical and mental 
component summary scores can range between 0 to 100, indicating worst and best health status, 
respectively. Mid point of 50 indicates average health comparable to norm values.  
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5.2.4 Adherence to Immunosuppressive Medications  
The BAASIS was used in the fourth section of the questionnaire to evaluate adherence to 
taking into account both implementation and discontinuation, and a visual analog scale ranging 
from ‘(0) no adherence’ to ‘(100) perfect adherence’.   
5.2.5 Instrument Pre-testing 
After developing the initial draft of the survey, members of the advisory committee and a 
transplant physician reviewed the questionnaire. Modifications were made to the questionnaire 
accordingly. Since the questionnaire consisted of previously validated tools to measure QoL, 
symptom experience and adherence, further testing in a transplant cohort was not required. The 
final electronic survey was tested on 10 laypeople using the survey platform, to confirm the 
functionality of the questions. 
REDCap survey platform has a limited forcing function capability, which displays a 
general message informing the respondent that they have missed a question. The message 
however, does not specify which specific question(s) were missed and does not prevent the 
respondent from proceeding to answer further questions. Therefore, respondents might have had 
missed answering some of the questions due to the survey length and the ambiguity of missed 
questions message or because they chose not to answer. 
5.3 Objective 3: Survey Pilot 
5.3.1 Response Rate 
The advance letter including the link to the survey was sent to 249 solid organ transplant 
recipient members of CTA. When the data collection period closed, a total of 127 questionnaires 
were received, resulting in a response rate of 51%. Fourteen participants did not fill out the SF-
12 or the BAASIS, while two respondents did not answer any of the BAASIS items. The 
remaining 111 participants (45 % of the entire population surveyed) completed the entire survey. 
The partially completed questionnaires were included in the analysis since the three tools used in 
this study (MTSOSD, SF-12, and BAASIS) each had a specific scoring and analysis 
recommendation. 
5.4 Objective 4: Descriptive Analysis 
5.4.1 Demographics of Respondents 
 The sample consisted of 71 (56%) males, and 56 (44%) females (Table 2). The average 
age of respondents was 55.5, ranging from 21 to 81 years. Most participants (85%) completed 
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some form of education after high school. The majority of the population (71%) was of European 
descent. Respondents were most commonly in a household income bracket of $40,000 – 60,000 
per year (20%), with only 4% reporting household incomes of less than $20,000. Most 
participants (76%) were married or in a common in law relationship.  
Table 2. Patient demographics 
Characteristic Total Population Men Women 
Count % Count % Count % 
Gender  127 100 71 55.9 56 44.1 
Age  Mean ± SD 
 
 Mean ± SD 
 
 Mean ± SD 
 
 
 55.5 ± 13.2  59.8 ± 11.8  50.0 ± 13.0  




 Grade 8 or less 1 0.8 1 1.4 0 0.0 
 Some high school 5 3.9 4 5.6 1 1.8 
 High school diploma 13 10.3 8 11.3 5 8.9 
 Registered apprenticeship 17 13.4 7 9.9 10 17.9 
 General & vocational college 44 34.6 25 35.2 19 33.9 
 University certificate 33 26.0 16 22.5 17 30.4 
 Bachelor’s degree 14 11.0 10 14.1 4 7.1 
Ethnicity 
 Aboriginal 4 3.2 4 5.6 0 0.0 
 Asian/South East Asian 2 1.6 1 1.4 1 1.8 
 South Asian 1 0.8 1 1.4 0 0.0 
 European 90 70.9 51 71.8 39 69.6 
 West Indian/Caribbean 1 0.8 1 1.4 0 0.0 
 Other 26 20.5 12 16.9 14 25.0 




Characteristic Total Population Men Women 
Count % Count % Count % 
Employment       
 Employed (full Time) 40 31.5 22 31.0 18 32.1 
 Employed (part Time) 12 9.5 6 8.5 6 10.7 
 Unemployed/looking 1 0.8 1 1.4 0 0.0 
 Unemployed/not looking 4 3.1 1 1.4 3 5.4 
 Retired/pensioner 43 33.9 33 46.5 10 17.9 
 Homemaker 4 3.2 0 0.0 4 7.1 
 Student 4 3.1 1 1.4 3 5.4 
 Not in work force 19 15.0 7 9.9 12 21.4 
Income ($)       
 Less than 20,000                                                              5 3.9 4 5.6 1 1.8 
 20,000 - 40,000                                               15 11.8 8 11.3 7 12.5 
 40,000 – 60,000                                              25 19.7 11 15.5 14 25.0 
 60,000 – 80,000                                              20 15.7 10 14.1 10 17.9 
 80,000 – 100,000                                            11 8.7 7 9.9 4 7.1 
 100,000 – 150,000                                          16 12.6 11 15.5 5 8.9 
 150,000 and above                                         16 12.6 10 14.1 6 10.7 
 Prefer not to answer                                      19 15.0 10 14.1 9 16.1 
Marital Status       
 Unmarried       17 13.4 5 7.0 12 21.4 
 Married/common law                                    96 75.6 61 85.9 35 62.5 
 Divorced/widowed/separated                      14 11.0 5 7.0 9 16.1 
Province of Residence       
 British Columbia 19 15.0 12 16.9 7 12.5 
 Alberta 29 22.8 13 18.3 16 28.6 
 Saskatchewan 15 11.8 14 19.7 1 1.8 
 Manitoba 1 0.8 1 1.4 0 0.0 
 Ontario 45 35.0 19 26.7 26 46.0 
 Québec city 10 7.9 6 8.5 4 7.0 
 New Brunswick 6 4.7 5 7.0 1 1.8 
 Nova Scotia 2 1.6 1 1.4 1 1.8 
 
5.4.2 Clinical Characteristics 
About a third (33%) of respondents reported receiving a liver transplant, while nearly a 
quarter received a kidney or a heart transplant (23%, and 22%, respectively) (Table 3). More 
than half of the respondents (61%) received their transplant over 6 years ago. The majority of 
respondents (61%) lived at least an hour’s driving time from their transplant center, and 28% 
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visited their transplant center twice a year compared to 33% who reported one or no visits per 
year. 
With respect to immunosuppressant therapy, 91% (115/127) of respondents were on a 
calcineurin inhibitor, and just over half were on a mycophenolic acid derivative, 55% (70/127) 
and prednisone, 51% (65/127). Of the transplant recipients who were taking calcineurin 
inhibitors, 65% (75/115) were on tacrolimus immediate release, and 12% (14/115) were on 
tacrolimus extended release, while an additional 23% (26/115) took cyclosporine. Of the 
respondents who were on a mycophenolic acid derivative, the majority (69%, 48/70) were taking 
mycophenolate mofetil, while 31% (22/70) took enteric-coated mycophenolate sodium. Other 
medications that were reported by the cohort included azathioprine 17% (22/127), followed by 
sirolimus 8% (10/127) everolimus 2% (2/127) and leflunomide (1/127). In addition to taking 
immunosuppressant medications, respondents reported an average of seven (±4.8) other 
medications per day.  
The majority of recipients (95%) reported that they had not been treated for transplant 
rejection, and felt that they had very good function of their transplanted organ (86%). The 
number of additional medical conditions ranged from 0-6 per respondent, with high blood 
pressure being the most common (reported by 48%). Fifteen percent of the population reported 
no other medical conditions. (Table 3). 
Table 3. Clinical characteristics 





Count % Count % Count % 
Organ Transplant Type 







 Liver 42 33.1 23 32.4 19 33.9 




19 26.7 9 16.1 




6 4.7 0 0.0 6 10.7 
Time to Transplant Center 
 Within 1 hr Driving 78 61.4 50 70.4 28 50.0 
 Within 3 hr Driving 29 22.8 12 16.9 17 30.4 
 Within 5 hr Driving 10 7.9 4 5.6 6 10.7 
 Greater than 5 hr 6 4.7 4 5.6 2 3.6 
 Other 
  









Count % Count % Count % 
Number of Visits to Transplant Center per Year 
 Less than once per year   12 9.4 8 11.3 4 7.1 
 Once 30 23.6 16 22.5 14 25.0 
 Twice 36 28.3 19 26.8 17 30.4 
 Three times 12 9.4 10 14.1 2 3.6 
 Four times 20 15.7 9 12.7 11 19.6 
 Five – six times 10 7.9 3 4.2 7 12.5 
 More than six times 7 5.5 6 8.5 1 1.8 
Time Since Transplant 
 Less than three months ago 1 0.8 0 0.0 1 1.8 
 Six months – one year ago 1 0.8 1 1.4 0 0.0 
 One- three years ago 10 7.9 4 5.6 6 10.7 
 Three- six years ago 37 29.0 19 26.8 18 32.0 




65 51.0 36 51.0 29 52.0 
 Mycophenolic acid derivative 
  
70 55.0 40 56.0 30 54.0 
o Mycophenolate mofetil 48 68.6 27 56.3 21 43.7 
o Enteric coated mycophenolate mofetil 22 31.4 13 59.0 9 41.0 
 Calcineurin inhibitors 115 91.0 64 90.0 51 91.0 
o Cyclosporine 26 22.6 20 77.0 6 23.0 
o Tacrolimus 89 77.4 44 49.4 45 50.6 
 M-tor inhibitors 12 9.5 7 58.3 5 41.7 
o Sirolimus 10 83.3 5 50.0 5 50.0 
o Everolimus 2 16.7 2 100.0 0 0.0 
 Azathioprine 22 17.0 13 18.0 9 16.0 
 Leflunomide 1 0.8 0 0.0 1 2.0 
Number of Doses of Medication per day 
 Once 3 2.4 1 1.4 2 3.6 
 Twice 79 62.0 45 63.4 34 60.8 
 Three times 23 18.1 15 21.0 8 14.3 
 Four times 10 7.9 6 8.5 4 7.0 
 Five times 5 3.9 2 2.8 3 5.4 










Count % Count % Count % 
Treated for Transplant Rejection 
 Yes 
  
4 3.0 0 0.0 4 7.0 
 No 
  
121 95.3 70 98.6 51 91.0 
 Unsure 
  
2 1.6 1 1.4 1 1.8 
Function of Transplanted Organ 
 Working very well 109 85.8 63 88.7 46 82.0 
 Working ok/some organ failure 10 7.9 5 8.9 5 8.9 
 Not working well/severe organ failure 8 6.3 3 4.2 5 8.9 
Other Medical Conditions* 
 Heart Condition 12 9.4 9 12.7 3 5.4 
 High Blood Pressure 61 48.0 36 50.7 25 44.6 
 Lung Disease 5 3.9 1 1.4 4 7.0 
 Diabetes 29 22.8 22 31.0 7 12.5 
 Ulcer or Stomach Disease 5 3.9 3 4.2 2 3.6 
 Bowel Disease 12 9.5 5 7.0 7 12.5 
 Kidney Disease 18 14.2 8 11.3 10 17.9 
 Liver Disease 3 2.4 2 2.8 1 1.8 
 Anemia or Other Blood Disease 9 7.0 1 1.4 8 14.3 
 Cancer 7 5.5 6 8.5 1 1.8 
 Depression 5 3.9 2 2.8 3 5.4 
 Osteoarthritis, Degenerative Arthritis 17 13.4 8 11.3 9 16.0 
 Back Pain 
  
18 14.2 10 14.1 8 14.3 
 None 19 15.0 11 15.5 8 14.3 
 Other Medical Problems 36 28.3 14 19.7 22 39.3 
Kidney Disease/Failure 
 No 81 63.8 51 71.8 30 53.6 
 Yes, Mild Kidney Disease 13 10.0 7 9.9 6 10.7 
 Yes, Moderate Kidney Disease 9 7.0 5 7.0 4 7.0 
 Yes, Severe Kidney Disease 2 1.6 0 0.0 2 3.6 
 Yes, On Dialysis 4 3.0 2 2.8 2 3.6 
 Unsure 1 0.8 0   1 1.8 
 I Have Had a Kidney Transplant1 17 13.4 6 8.5 11 19.6 
* Respondents were allowed multiple answers for these questions 1All participants were asked whether they had 
some degree of kidney disease, which is commonly caused by immunosuppressive medications. Many patients that 




5.4.3 Symptom Experience 
 Respondents reported a median of 19 different adverse symptoms (IQR= 12- 27). In 
addition to the symptoms included on the MTSOSD, eight individuals reported additional 
symptoms that were not covered by the questionnaire. Two respondents reported tinnitus with a 
moderate level of distress, while another participant reported the occurrence of dry eyes, and 
peeling of skin of hands (reported as mildly distressing). Loss of sense of smell, agitation, bone 
weakness, and white outs, were also reported (each by one individual), and were all considered 
highly distressing. 
Adverse Symptoms Occurrence and Distress  
Respondents were asked to indicate whether they had experienced the adverse effect 
within the last four weeks on a scale of ‘never (0)’ to ‘always (4)’. Symptoms prevalence was 
reported as the proportion of people who reported the occurrence of the symptom (scores of 1 
and higher). Symptoms were then classified into tertiles according to occurrence (high, medium, 
and low occurrence), while associated distress via each of symptom was presented as mean 
score. Tables 4 and 5 depict the tertiles of symptom occurrence, arranged in descending order of 
distress for female and male respondents, respectively.  
In both women and men, the most frequently reported commonly perceived symptoms 
were tiredness, flatulence, and lack of energy (reported at an incidence of 84%, 82% and 70% for 
women and 80%, 76%, and 66% for men, respectively).   
The most prevalent symptoms were not necessarily the most distressing ones. In women, 
flatulence occurred in over 80% of the population, but was not perceived to be very distressing 
(mean 1.5 on a scale of 0 to 4). Diarrhea, however, occurred in 50% of the population, but was 
moderately distressing (mean 2.5/4). The most distressing adverse symptom in women was 
genital warts (mean 3.5/4), yet this symptom was only reported in 7% of respondents.  Some 
distress levels were gender specific. For instance, breast enlargement occurred in a higher 
prevalence in men compared to women (13% vs. 5%), and men found the symptom to be more 
distressing (2 compared to 1/4, respectively). In men there seemed to be more consistency 
between occurrence and distress, as the most prevalent symptoms were usually the more 
distressing ones. With the exception of genital warts and puffy face in females (3.5/4 and 2.7/4, 



















1.1-2.0 spots on face/neck 
oily skin 
constipation 
change in sense of taste 
altered voice 
fat on neck/back 
change in appearance 














↑ hair growth 
















2.1-3.0 menstrual problems 
skin rash 
puffy face 











lack of energy 
diarrhea 
joint pain 
3.1-4.0 genital warts   
Symptom prevalence represents the proportion of patients that have experienced the adverse symptom (i.e. 
respondents who chose ‘occasionally’, ‘regularly’, ‘almost always’ or ‘always’ for symptom occurrence). 
Symptoms within each prevalence category were arranged from lowest to highest distress (scale=0 to 4).
39 
 










0.0-1.0 genital warts 
swollen glands 
  
1.1-2.0 change in appearance 












abnormal skin color 
warts on hands/feet 
↑ hair growth 








































2.1-3.0   erectile problems 
sleeplessness 
lack of energy 
flatulence 
tiredness 
3.1-4.0    
Symptom prevalence represents the proportion of patients that have experienced the adverse symptom (i.e. 
respondents who chose ‘occasionally’, ‘regularly’, ‘almost always’ or ‘always’ for symptom occurrence.). 




In a sensitivity analysis, we re-examined prevalence of adverse symptoms after applying 
a stricter definition of occurrence (i.e., only symptoms rated as the most prevalent symptoms 
identified by patients as a 3 or 4 (almost always or and always were counted)) (Table 6). In 
women, the three most prevalent adverse symptoms were dryness of skin, tiredness and reduced 
interest in sex (25%, 24% and 21% reported as almost always or always, respectively), while in 
men the three most prevalent symptoms were erectile problems, sleeplessness, and brittle skin 
(18%, 16% and 13%, reported as almost always or always, respectively). Tiredness (in women) 
was the only symptom that remained in the top three, when using the more stringent definition of 
occurrence. Also, the overall prevalence of adverse symptoms now reached only 25%, compared 
to the original definition, which resulted in an adverse event rate up to 84%.  
 
Table 6. Top 10 adverse symptoms reported by women and men, according to the definition of 
‘almost always and always’ on the occurrence scale 








dryness of skin 25.0 erectile problems 18.3 
tiredness 23.6 sleeplessness 15.5 
↓interest in sex 21.4 brittle skin 12.7 
lack of energy 19.6 lack of energy 11.3 
sleeplessness 18.0 bruises 11.3 
brittle fingernails 18.0 ↓interest in sex 11.3 
muscle weakness 18.0 flatulence 10.0 
trembling hands 16.0 joint pain 10.0 
bruises 16.0 trembling hands 10.0 






Causal Attribution of Adverse Symptoms:  
Respondents were asked whether they attribute their adverse symptoms to 
immunosuppressant medications, other medications, and their medical conditions on a Likert 
scale of ‘strongly agree’ to ‘strongly disagree’. For respondents that agreed or strongly agreed 
with immunosuppressants as a symptom cause, the specific immunosuppressant medications 
identified in the demographic section of the survey were presented in a follow up question to 
probe further into patient perceptions of each agent’s role in causing the adverse symptom.  
Overall, medical conditions were perceived to be the leading cause of adverse symptoms, 
followed by immunosuppressant medications, and other medications, respectively (Figure 2). 
Shortness of breath, poor appetite and lack of energy were perceived to be the top three 
symptoms caused mainly by medical conditions, while menstrual problems, fat deposits on neck 
and back, and muscle weakness were perceived to be caused by other medications. The top three 
symptoms perceived to be caused by immunosuppressant medications were warts on hands and 












Figure 2. Causal attribution of adverse symptoms 
 
 This figure presents the percentage of respondents that agreed or strongly agreed with the 3  potential causes for each 
adverse symptom. 






































change in appearance (n=11)
fat deposit on neck & back (n=11)
poor memory (n=76)


















decreased interest in sex (n=47)
sensitivity to light (n=29)
heartburn (n=36)
immunosuppressants other medications medical conditions
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Figure 3. Top 10 symptoms attributed to immunosuppressants, other medications and medical 
conditions 
 
This figure presents the top 10 symptoms attributed to immunosuppressants, other medications and medical 
conditions, according to the percentage of respondents that ‘agreed’ or ‘strongly agreed’.  The X-axis presents the 
ASI, where n= the number of respondents who reported the symptom. The Y-axis presents the percentage of 








Of the respondents that were taking calcineurin inhibitors (cyclosporine or tacrolimus), 
trembling hands, warts on hands and feet, and fat deposit on neck and back were the most 
common symptoms attributed to these medications. The leading adverse symptoms perceived to 
be caused by corticosteroids (prednisone) were  puffy face, increased appetite and hair growth. 
The top 10 symptoms attributed to be caused by each immunosuppressive class are listed in 
figure 4. It should be noted that these results should be taken into context of the number of 
patients experiencing the symptoms. For instance, the top 4 ASI perceived to be caused by 
mycophenolic acid derivatives (mycophenolate mofetil and enteric coated mycophenolate 
sodium) were redness on face and neck, warts on hands and feet, abnormal skin colour and 
altered voice (reported by 65%, 65%, 50% and 50%, respectively). These symptoms, however, 
were only reported by a small number of participants (n=3, n=9, n=4, and n=2, respectively).  
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Figure 4. Immunosuppressant medications groups' attribution of adverse symptoms to 
immunosuppressant medications 
 
This figure presents the top 10 symptoms attributed to specific immunosuppressant medications. The X-axis 
presents the ASI, where n= the number of respondents who reported the symptom. The Y-axis presents the 
percentage of respondents that ‘agreed’ or ‘strongly agreed’. 
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Adverse symptoms were not consistently reported among patients taking 
immunosuppressants from the same medication classes. For instance, respondents taking 
cyclosporine reported increased hair growth (78%), swollen gums (67%) and trembling hands 
(63%) as the top three attributed adverse symptoms, whereas respondents taking tacrolimus 
reported trembling hands (72%), warts on hands and feet (55%), and spots on face/neck (40%). 
Figures 5, 6 and 7 highlight these differences by comparing ASI attributed to specific agents 
within class. As with figure 4, the number of patients experiencing the symptoms should be 
taken into account when considering these results.  
 
Figure 5. Calcineurin inhibitors attribution to adverse symptoms 
 
This figure presents the top 10 symptoms attributed to tacrolimus and cyclosporine, according to the percentage of 
respondents that ‘agreed’ or ‘strongly agreed’. The X-axis presents the ASI, where n= the number of respondents 
who reported the symptom. The Y-axis presents the percentage of respondents that ‘agreed’ or ‘strongly agreed’. 
 




Figure 6. Mycophenolic acid derivatives attribution to adverse symptoms 
 
This figure presents the top 10 symptoms attributed to enteric-coated mycophenolate sodium and mycophenolate 
mofetil, according to the percentage of respondents that ‘agreed’ or ‘strongly agreed’. The X-axis presents the ASI, 
where n= the number of respondents who reported the symptom. The Y-axis presents the percentage of respondents 








Figure 7. M-tor inhibitors attribution to adverse symptoms 
 
This figure presents the top 10 symptoms attributed to sirolimus and everolimus, according to the percentage of 
respondents that ‘agreed’ or ‘strongly agreed’. The X-axis presents the ASI, where n= the number of respondents 
who reported the symptom. The Y-axis presents the percentage of respondents that ‘agreed’ or ‘strongly agreed’. 
 
 
 Adverse Symptoms Treatability: 
Respondents reported the perceived treatability of each adverse symptom on a Likert 
scale of ‘strongly agree’ to ‘strongly disagree’. The percentage of participants who agreed, or 
strongly agreed was calculated for each of the adverse symptoms. Lack of energy, warts on 
hands and feet, and headaches were ranked the highest in terms of treatability, as reported by 
30% (13/39 women, 13/47 men), 72% (6/9 women, 7/9 men), and 72 % (22/34 women, 22/27 
men), respectively. On the other hand, breast enlargement, changed taste, and nightmares 
received the least proportion of ‘strongly agree’ and ‘agree’ responses by 0% (0/3 women, 0/9 









Figure 8. Treatability of adverse symptoms 
 
Figure 7 represents the proportion of respondents who ‘strongly agreed’ or ‘agreed’ when asked whether each 




5.4.4 Quality of Life: 
One hundred and thirteen transplant recipients (89% of respondents) completed the 
health-related QoL section, including 63 men and 50 women. The adjusted norm-based values 
(with a score of 50 equating to the US average ± standard deviation of 10) are presented in table 
7, while Figure 8 indicates the percentage of patients that were above, at or below the population 
norm for the physical and mental component summaries (PCS and MCS). Both women and men 
reported a comparable physical component summary (47 and 48, respectively) and mental 
component summary (51 and 53, respectively) relative to a population norm.  Women and men 
also reported a good overall general health (51 and 53, respectively) and good mental health (51 
and 54, respectively).  















Respondents provided feedback on physical and mental health status, ability to do usual activities and how they rate 






Short Form-12 (SF-12) items Women scores Men scores 
Physical component summary (PCS) 46.5 48.1 
physical functioning (PF) 46.5 48.2 
role physical (RP) 44.9 46.9 
bodily pain (BP) 48.5 50.3 
general health (GH) 51.3 52.5 
Mental component summary (MCS) 51.0 52.9 
vitality (VT) 48.7 50.6 
social functioning 48.9 51.3 
role emotional (RE) 48.9 49.5 
Mental health (MH) 51.0 53.9 
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Figure 9. Comparison of QoL scores to general population norms 
 
 
5.4.5 Self-Reported Adherence: 
Over half (56%) of the respondents answered ‘yes’ to at least one of the four BAASIS 
questions, and were therefore categorized as nonadherent. Most cases were related to 
implementation of medication taking: 38% had missed a dose in the last four weeks, 4% have 
skipped two or more doses, 37% had taken their medications two hours before or two hours later 
than scheduled. One female transplant recipient (1% of total population) reported discontinuing 
at least one medication. Females and males were found to have similar rates of nonadherence 
(57%, and 55%, respectively) (Table 8). However, according to the visual analogue scale, more 
than two thirds of respondents (78%) reported that they had taken their immunosuppressive 







Table 8. Self-reported adherence to immunosuppressant medications 
1a. Implementation: Do you remember missing a dose of any of your anti-rejection 
medications in the last 4 weeks? 
 Women (n=49) Men (n=62) Total (n=111) 
Yes 41.0% (20) 36.0% (22) 37.8% (42) 
(If yes): Can you remember how often this happened? 
Once 55.0% (11) 59.0% (13) 57.0% (24) 
Twice 20.0% (4) 18.0% (4) 19.0% (8) 
Three times 20.0% (4) 9.0% (2) 14.3% (6) 
Four times 0.0% (0) 4.5% (1) 2.4% (1) 
>Four times 5.0% (1) 9.0% (2) 7.0% (3) 
1b. Do you remember having skipped two or more doses of your anti-rejection medications in 
a row in the last 4 weeks? 
Yes  4.0% (2) 3.0% (2) 3.6% (4) 
(If yes): Can you remember how often this happened?  
Once 50.0% (1) 50.0% (1) 50.0% (2) 
Twice 50.0% (1) 0.0% (0) 25.0% (1) 
Four times 0.0% (0) 50.0% (1) 25.0% (1) 
2. Your anti-rejection medications need to be taken at specific times, recommended by your 
transplant team. Do you remember having taken your anti-rejection medications more than 2 
hours before or after the recommended dosing time in the last 4 weeks? 
Yes 36.7% (18) 37.0% (23) 36.9% (41) 




Once 10.0% (5) 14.5% (9) 34.0% (14) 
Twice 14.3% (7) 11.3% (7) 34.0% (14) 
4-5 times 8.8% (4) 9.7% (6) 24.4% (10) 
Every 2-3 days 4.0% (2) 1.6% (1) 7.3% (3) 
Almost daily 0.0% (0) 0.0% (0) 0.0% (0) 
3. Have you altered the prescribed amount of your anti-rejection medications during the last 4 
weeks, without your doctor telling you to do so? 
Yes 4.0% (2) 1.6% (1) 2.7% (3) 
4. Discontinuation: Have you stopped taking your anti-rejection medications completely 
within the last year, without your doctor telling you to do so? 




           
Figure 10. Self-reported adherence using the visual analog scale (VAS) score 
 
 This graph represents the percentage of women and men who reported different scores on the visual analog scale 
when asked: ‘how well did you do in the last 4 weeks with taking their anti-rejection medications using a visual 
analog scale, where 100% is ‘always took medication as prescribed’ and 0 is ‘never’?’ 
5.5 Objective 5: Assess Feasibility 
5.5.1 Response rate:  
The survey was sent electronically to 249 members of the Canadian Transplant 
Association. A total of 127 questionnaires were returned achieving a response rate of 51% 
(127/249), exceeding our target response rate of 40%.  
5.5.2 Missing of data:  
 Almost 71% of the survey respondents completed the entire questionnaire. The 
breakdown and description of missing data is reported in table 9. The questions that were most 
commonly missed were the causal attribution of adverse symptoms, as well as the as quality of 






























Figure 11. Summary of missed questions for returned surveys 
 
5.5.3 Patient feedback 
Forty transplant recipients (32%) provided open-ended comments. After a thorough 
review of the qualitative data, the following themes emerged: 1) Demographics and Clinical 
Conditions, 2) Survey Design, 3) Technical Issues. 
Theme 1: Demographics & Clinical Conditions 
Twelve respondents commented that many of their answers were influenced by the 
presence of other diseases or medical conditions. They believed their other medical conditions, 
or the medications used to prevent/treat them impacted their responses. For instance, patient#6 
responded: “[I am] presently limited with activity due to having surgery on my ankle and still 
recovering. Also on pain medications, therefore; a few questions like constipation and some 
mood effects that I wouldn’t normally experience, have been answered with yes but are normally 
a no”. 
Transplant recipients (n=5) also acknowledged the influence of time since transplant with 
respect to symptom experience. Patient#6 stated,” I have noticed that I would have experienced 
tons of adverse symptoms immediately after my transplant, some I would have experienced over 
the next five year period, then some I didn’t experience until I hit about 15 years post-
transplant”. According to patient#49, “In my case I had most of the complications and side 
effects in the first two years after transplant, time and treatment solved most of the issues and 























number of missed questions
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Some respondents (n=5) indicated that many of their adverse symptoms could be age-
related. As stated by patient#7: “My responses for many of the questions reflects my age, seventy 
five years old”, and patient#105: “My age may be the reason for a number of my medical 
problems, or may not”. 
Theme 2: Survey Design 
Three respondents suggested having more open ended questions, adding more space for 
elaborated answers and comments, and adding an ‘Unsure’ option to the answers. One of the 
respondents suggested replacing the 61 adverse symptoms with a blank space where patients can 
report their own experienced side effects. Patient #35: “I think your data quality would be greatly 
improved if you asked the questions: Do you experience (symptom x)? If yes, do you think this is 
a side effect of your medications? If yes, then expand the list”. Patient#21 responded, “[It was] 
hard to answer some of the questions. For example, some are not yes/no questions and perhaps 
after the first section there should be a comment section”. 
While three respondents described the survey as lengthy, they felt this was necessary to 
cover the many adverse symptoms experienced by transplant recipients. Patient#61: “I thought it 
was a little long, but it did ask very relevant questions”. Patient#101 responded, “This is a 
daunting survey. It is very long, mainly because of the many-many side effects that these 
medications can cause. I would suggest breaking up the pages even more so that they can be 
saved and come back to it more often”. 
Theme 3: Technical Issues 
During the data collection phase of the study, we received feedback from a couple of 
respondents that the survey could not be completed on an iPad, which was an inconvenience. 
One respondent also filled out the survey using his cell phone, and acknowledged having some 
issues. These technical difficulties may have been caused by the complex skip logic/branching of 
the symptom experience questions.  
A couple of respondents commented that there was a technical error regarding the skip 
logic (i.e. immunosuppressive medications that were not chosen by the respondent were still 
displayed when they should not have been). As noted by patient#91 “Imuran popped up on one 
of the questions even though I don’t take it and didn’t identify that I took it”.  
A few other technical comments were reported as well:  
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Patient#117 “This survey wasn’t mobile friendly and numerous times I would chose my answer 
and have to wait a few minutes before the question would expand to explain my answer”. 
Patient#127“If a question is missed, please bring up that question only or highlight it rather than 
having us have to scroll through the full page”. 
Patient#17“When a person misses a question, it should give a question number to go back to not 


























CHAPTER 6: DISCUSSION 
The results of this pilot indicate that it is feasible to assess symptom experience, quality 
of life, and adherence to immunosuppressants in a cohort of solid organ transplant recipients 
using a single electronic survey.  The pilot involved representatives of varying ages, transplant 
type and provincial location, and achieved a satisfactory response rate of 51%. Data analysis was 
completed within a reasonable amount of time, and 71% completed the entire questionnaire 
without missing a question. 
This pilot study also identified issues that require more attention prior to undertaking a 
multicenter study. Further review and testing is recommended to improve the questionnaire 
design, and technical issues identified by the respondents. A subgroup analysis should also be 
incorporated into the statistical plan, to evaluate any association between age, other medical 
conditions and time post-transplant on symptom experience, QoL, and nonadherence to 
immunosuppressive medications. 
Transplant recipients face several new challenges after transplantation. Transplant 
recipients may experience ASI, which can impact their physical and psychological well-being 
and health-related quality of life. ASI may also contribute to nonadherence to prescribed 
immunosuppressants, consequently leading to rejection and graft loss. It is essential for health 
care professionals to assist patients with adapting to post-transplant changes and to develop 
strategies to manage ASI, to maximize transplant recipient’s general health. Our descriptive 
study was designed to explore transplant recipient’s perceptions on their symptom experience, 
quality of life and nonadherence to immunosuppressive medications. This chapter presents a 
discussion of the study results in four principal sections: 1) tool identification, questionnaire 
development and piloting, 2) descriptive analysis, 3) feasibility of future multicenter study, 4) 
strengths, and limitations. 
6.1 Tool Identification, Survey Development and Piloting  
Since this was the first study to evaluate symptom experience, quality of life, and 
nonadherence to immunosuppressive medications in a group of solid organ transplant recipients  
there was no pre-existing tool to measure the three areas collectively. Therefore, a literature 
review was undertaken to identify quantitative tools that were previously used in transplant 
literature to measure these target areas. Our final questionnaire was comprised of the MTSOSD, 
58 
 
SF-12, and BAASIS to measure symptom experience, quality of life, and nonadherence to 
immunosuppressive medications, respectively. 
The three tools used in our questionnaire were validated in previous literature (MTSOSD: 
transplant recipients, SF-12: dialysis population, BAASIS:  chronic conditions (HIV- 
positive),45,48,49,87,118,119 therefore the research team decided not to revalidate the final tool; 
instead it was revised and edited by the advisory committee and a transplant physician. 
Furthermore, the questionnaire was tested by10 lay people and finalized.  
6.2 Descriptive Analysis 
6.2.1 Respondents Demographics and Clinical Situation 
Participants in our survey had similar demographics to those reported in US and 
European registries of solid organ transplant populations in terms of age, sex, and ethnicity 
(Table 10).120,121 Our study population was notably different, however, in that there was a higher 
proportion of liver (33%) and heart (23%) transplant recipients and a lower proportion of kidney 
(23%) transplant recipients.   
 Since immunosuppressive medication regimens may differ by organ, caution is needed 
when generalizing these findings to other transplant populations with a different organ 
composition. Time since transplant should also be taken into consideration when extending our 
findings to other populations. The average time since transplant in our study was more than 6 
years. Since immunosuppression and symptom experience can change over time, these results 
may not reflect the experiences of patients who were more recently transplanted.   
Table 9. Demographic and clinical variables according to Canadian, American and European 
registries versus our study population 
 Canadian Institute 
of Health 
United Network 









NA 62% NA 55% 




NA European decent 
56% 
NA European decent 
71% 
Transplant type 
(by % organ) 
Kidney      59% 
Heart          6% 
Liver         22% 
Kidney        58% 
Heart             9% 
Liver           23% 
Kidney      56% 
Heart           9% 
Liver         24% 
Kidney        23% 
Heart           23% 




6.2.2 Symptom Experience 
To define the most commonly occurring symptoms, prevalence was calculated as the 
percentage of respondents that reported the occurrence of the symptom. Our approach was 
consistent with a previous study of kidney transplant patients from European transplant centers 
(n= 1209) that reported symptom occurrence in prevalence (percentage of respondents who 
reported any occurrence of the adverse symptom, meaning 1 or more).52 Likewise, a study of 
HIV positive patients used this approach to identify the most commonly occurring adverse 
symptoms.122 To describe symptom distress we used the mean score for each symptom, which is 
similar to how distress was defined in the previously mentioned HIV positive study.122  
In our study, the most prevalent symptoms in women and men were tiredness, flatulence, 
and lack of energy. This finding is consistent with previous studies that have used the 
MTSOSD.14,30,52 A study of kidney transplant recipients (n=356) in Switzerland found that 
tiredness was the most common symptom,14 while another study (n= 261) reported tiredness 
(88.8%) and lack of energy (79.5%) as the most prevalent symptoms in heart transplant 
recipients.30 Likewise, a study investigating symptom experience in 543 kidney transplant 
recipients reported the most prevalent symptoms to be flatulence (73.9%), tiredness (73.0%) and 
lack of energy (63.9%).52  
The most prevalent symptoms were not necessarily the most distressing in our study. 
Although they occurred infrequently (7%), women in our study reported genital warts as the 
most distressing symptom, same for skin rash (prevalence 11%, distress 2.2 on a scale of 0 to 4) 
and menstrual problems (prevalence 13%, distress 2.1 on a scale of 0 to 4). Amongst men, 
tiredness, flatulence, and erectile problems were both frequent and distressing 
(prevalence/distress 80% /2.2, 76% /2.2 and 49% /2.1, respectively). These results are similar to 
another study of 261 heart transplant recipients, in which tiredness, lack of energy and 
nervousness were reported to be the most common symptoms by men and women, while the 
most distressing symptoms were erectile dysfunction in men, decreased interest in sex (men and 
women) and muscle weakness in men.30 This is also similar to the findings of a study in 
 356 kidney transplant recipients, where women reported painful menstruation, rash and mouth 
infections and men reported anxiety, mouth infections and swollen gums as least frequent/highly 
distressing.14 It is interesting to note that, in general, our participants seemed to report a good 
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overall QoL comparable to general public despite high prevalence of adverse symptoms and the 
associated perceived distress. A similar study (quantifying distress using the same approach) in a 
more acute population would be interesting, since our transplant recipients on average were 
transplanted at least six years ago.  
Even general comparisons of symptom prevalence and distress between previous research 
and our results are somewhat difficult, since previous studies used different definitions and 
analysis to characterize symptom experience (occurrence and perceived distress). Our findings 
seem to be in line with transplant literature in that female respondents reported more symptoms 
and a higher perceived distress than men.16,47-49 
Causal attribution and treatability of adverse symptoms from the perspective of transplant 
recipients were of particular interest in this study. Since the literature is sparse regarding these 
aspects of patient perception and we could not find any studies addressing patient perception of 
symptom causal attribution and treatability in solid organ transplant recipients, we looked into 
the literature of other chronic diseases. In a study of HIV-positive adult patients exploring the 
symptom causal attribution, participants mainly attributed their adverse symptoms to HIV 
infection, followed by antiretroviral medications.122 Our transplant recipients primarily attributed 
their adverse symptoms to their medical conditions, followed by immunosuppressive 
medications and other medications. Our survey tool asked patients to identify which specific 
immunosuppressant was perceived to be the causative factor.  In many cases, respondent’s 
perceptions of the cause of specific side effects were consistent with the literature.  For example, 
corticosteroids were frequently identified as a cause of puffy face, increased appetite and hair 
growth; cyclosporine was identified as a cause of increased hair growth, tacrolimus caused 
trembling hands, and sirolimus caused stomach disturbances.  In contrast, some drugs were 
blamed for side effects that were not reported in the literature; azathioprine was cited as the 
cause of breast enlargement and joint pain but no such association could be found in the product 
monograph.  Similarly, oral sores, spots on face and neck, and skin rash were attributed to 
mycophenolic acid derivatives where no such link could be found in the product monograph or 
other literature.  It is not clear whether patients attribute adverse events to specific drugs because 
of a personal evaluation of their symptoms or if they are basing these associations on their 
knowledge of drug side effects reported in drug information materials. Understanding how 
patient experiences, expectations and knowledge may influence their symptom experience would 
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be very valuable. Future research is needed to determine whether the perceived cause of adverse 
symptoms is associated with lower medication adherence. 
Treatability of adverse symptoms from a patient perception is another understudied area 
in the literature of chronic conditions. Our sample perceived lack of energy and warts on hands 
and feet to be the most treatable symptoms, while breast enlargement and changes in sense of 
taste received the least agreement on their treatability. This information is of value and utility for 
health care providers as understanding the patient’s perception on cause and treatability of ASI 
may ultimately assist with understanding underlying factors that may contribute to 
nonadherence. For instance, if an immunosuppressive medication is largely perceived to 
responsible for causing an ASI that is particularly bothersome and this ASI is not perceived to be 
treatable, patients may be more likely to stop this medication.  To our knowledge, this study is 
the first to investigate cause and treatability from a patient perspective, and we believe more 
research should be undertaken in this area. 
6.2.3 Quality of Life  
Since patient perceptions of ASI may influence their reported QoL, it was important for 
us to investigate this concept in this research. Interestingly, participants in this study reported 
comparable health-related quality of life to that of general public. Most of the previous studies in 
this area have noted transplant recipients to have a similar or slightly lower QoL to that of the 
general public. In a study of heart transplant recipients, however, participants reported a higher 
physical (57.0) and mental quality of life (58.0) than normal population,84 which may be due to 
the fact that patients in this study were 20 years or more post-of transplant and those who 
received a re-transplantation or a multi-organ transplants were excluded. In our population, the 
mental component summary scores (MCS) were reported as 51.4 and the physical component 
summary scores (PCS) were 47.4. This trend was consistent with another study of 722 solid 
organ transplant recipients that used SF-12 to evaluate QoL, which revealed a MCS score of 50.2 
and PCS score of 42.6.55  
The World Health organization definition of quality of life focuses primarily on the 
subjective perception of individuals that may be guided by physical, psychological state and 
personal beliefs. Thus, the positive QoL scores reported in this study may be due to our sample 
of generally healthy, stable transplant recipients.  In general, the members of the CTA are a 
highly functional and active group of recipients that advocate for organ donation and are 
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involved in national and international transplant Olympic games. A study conducted in the 1990s 
assessing QoL in transplant recipients who were competing in United States Transplant Games 
found similar results, as participants reported a comparable overall QoL to that of the general 
population.123 Another explanation for the positive QoL scores reported in this study maybe due 
to transplant recipient’s perception of improvement from their pre-transplant situation. 
Transplant is a lifesaving procedure for many, which reduces the physical and economic burden 
for medical procedures such as dialysis. Hence, QoL scores would be expected to improve after 
transplant. A study of kidney transplant recipients used the Crisis theory as a conceptual 
framework to justify this idea.124 More specifically, the Crisis theory suggests that the QoL of 
people in crisis deteriorates, therefore they are more willing to try new coping methods and learn 
to adapt to their situation which leads to a QoL which is comparable or even better to that of less 
severely ill patients or healthy individuals in subsequent stages of the disease.125 The 
aforementioned study of kidney transplant recipients included three different groups: Candidates 
waiting for transplant (n=45), transplant recipients (n=99) and non-transplant population (n=82). 
124 The finding was in agreement to our finding, as transplant recipients reported a better QoL 
compared to candidates on the wait list with end stage organ failure, and a comparable QoL to 
non-transplant recipients. It is reassuring that the transplant recipients in our study reported a 
comparable QoL to general population even though they were taking an average of seven 
medications and reported a median of 19 different adverse symptoms.  
6.2.4 Adherence to Immunosuppressive Medications 
The overall self-reported nonadherence rate was 56% in our population. This seems to be 
consistent with the results of a study of kidney transplant recipients (n=62), in which respondents 
reported an overall nonadherence of 65% using BAASIS dichotomous scale.110 On the other 
hand, participants in our study reported a lower nonadherence rates using the visual analog scale, 
as 78% of participants reported 90-100% adherence to immunosuppressive medications. The 
possible explanation for the differences in overall adherence using dichotomous (answers of the 
four questions) versus continuous approach (the visual scale) could be due to the strict definition 
of nonadherence, according to the dichotomous approach; any yes answer to one of the four 
questions classifies the respondent as non-adherent. The discrepancies between the dichotomous 
approach and the visual analogue scale have been noted in two other studies. In the previously 
mentioned study of 62 kidney transplant recipients, 65% of respondents reported nonadherence 
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to immunosuppressive medications using the dichotomous scale, while the median overall 
adherence reported using the visual analog scale was 99.5%.110 In another study of 238 solid 
organ transplant recipients, of 35.3% reported nonadherence on the dichotomous scale, while 
they reported a high overall adherence (median scores of 95%) using the continuous visual 
analog scale. 104 It should be noted that the results of the BAASIS dichotomous cannot be 
directly compared to those of the continuous scale since there is no threshold score for non-
adherence on the continuous visual analogue scale.  This is because it is impossible to define the 
level of non-adherence that would result in negative clinical consequences – i.e. there is no 
“acceptable” level of non-adherence.  
Adherence to immunosuppressive medications is fundamental to graft survival and 
improving outcomes. However, measuring nonadherence is a controversial topic as there are 
different methods following different definitions for nonadherence. Solid organ transplant 
relevant methods can be classified into direct or indirect. Direct methods involve measuring 
levels of drug or metabolites in the blood or urine, which requires a clinical setting. A downside 
to those methods is their high cost in terms of labour and laboratory work. Inaccurate results may 
be obtained as a result of medication timing – i.e. if the patient ingested their medication 
immediately before blood sampling.126 Indirect methods include patient self-report, reports from 
physicians or family members, refill rates, pill counts, or electronic monitoring.126 Most of the 
indirect methods are economic and easy to use but may be less sensitive, except for electronic 
monitoring which is a technologically advanced method that registers the opening of medication 
bottles. Opening the bottle, however, cannot definitively confirm that the patient actually took 
the medication. Interestingly, one study has shown that that transplant recipients seem to over 
report nonadherence using self-reported methods compared to electronic monitoring and assay 
values.104 Many authors have recommended combining direct methods of measuring along with 
self reported tools to measure adherence in order to improve accuracy, Still, there is no agreed on 
gold standard to measure nonadherence to immunosuppressive medications and discrepancies 
may occur as a result of the method of measure, so it is difficult to compare our study results to 
other studies. Nevertheless, the purpose of this study was to capture the perspectives of patients, 
and the data obtained from the self-reporting adherence scale provides valuable information 
about our cohort’s perceptions of adherence.  
64 
 
6.3 Feasibility of Future Multi-Center Study 
This pilot study provided important insights on transplant recipient’s perceptions of 
symptom experience, quality of life and nonadherence to immunosuppressive medications. A 
future multicenter study, however, should be undertaken to assess these aspects in a more diverse 
population. Our study response rate of 51% and the completion rate of 71% were acceptable, 
considering the length of the questionnaire. Based on response rate and completion rate alone, 
our results suggest that it could be feasible to use this questionnaire for future studies. 
Nevertheless, several other considerations would be required to complete this survey in a 
healthcare setting. Administering a paper copy of this questionnaire is not an option due to the 
questionnaire’s length, and the complex skip logic required for many of the questions. 
Consequently, a laptop or a tablet would be needed for participants to fill out the survey, and a 
research assistant, or dedicated staff member would be necessary to distribute devices to those 
who need them.  Completing this survey requires undivided attention and time, which may be 
difficult for patients in a busy dynamic clinic setting. Hence the arrangement of an assigned 
space would need to be considered to administer this questionnaire in a clinic or hospital setting. 
The associated expenses to these details needs to be accounted for when planning a future study. 
Another idea to consider with the cost and time investment would be to conduct the survey in an 
interview setting, minimizing complexity and resolving any clarity issues. 
Our experience with the pilot study helped us to understand ways in which the survey 
could be improved. For instance, for the symptom causal attribution questions we asked the 
respondent to rate whether ‘immunosuppressive medications’, ‘other medications’ and ‘medical 
conditions’ caused each ASI, using a separate Likert scale for each potential cause. In the future, 
we could consider combining the three questions, or asking the participant whether they believe 
each symptom is a side effect of the immunosuppressive drug(s), as suggested by patient #35. 
This will help eliminate unnecessary length of the questionnaire and reduce the time needed for  
questions to load. Some patients in our study also indicated that they had difficulties attributing 
their adverse symptoms to a specific immunosuppressive medication, and suggested we include 
the option of ‘I don’t know’. This feedback will be taken into consideration for the next stage of 
the project.  
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6.4 Strengths and Limitations  
Identifying transplant recipient’s perception of their post-transplant life is important for 
designing any future interventions. Our study adds to existing literature by highlighting 
prevalence, perceived distress in a sample of solid organ transplant recipients, and exploring new 
aspects to symptom experience by gathering feedback on causality and treatability of symptoms.  
Moreover, it also evaluated QoL and nonadherence to immunosuppressive medications. 
A distinction of this study is that it is the first study to evaluate symptom experience, 
QoL and nonadherence to immunosuppressive medications in a national cohort of solid organ 
transplant recipients, achieving an excellent response rate and a high attrition rate for the survey 
completion. Variables were measured using instruments with established validity in chronic 
illnesses populations, which enhances the quality of the results.  
Several limitations of this study need to be considered. Convenience sampling was used 
to recruit participants for this study and targeted adult solid organ transplant recipient members 
of the Canadian Transplant Association. Patient demographics and our observed results suggest 
that this cohort likely represents a healthier, more stable population than the average transplant 
recipient. Furthermore, the results may be subject to volunteer bias, suggesting that within our 
sample, patients who are more stable were more likely to complete the survey compared to those 
who are in a worse health condition.127 As previously discussed, caution is warranted when 
generalizing the results of this study to other populations. 
 A self-reported questionnaire was used in this study, which has its own challenges. 
Although the survey was anonymous, it is possible that participants may have responded to the 
questionnaire in manner they perceived to be more positive or acceptable, way, rather than 
providing an honest description of their experiences. The adherence section may be particularly 
vulnerable to this type of bias. Since many of the questions in this instrument are subjective 
rather than factual, patients may interpret the Likert scales used in the study differently. For 
instance, with respect to perception of ASI, what one person might consider severe, another may 
consider mild or moderate, leading to discrepancies in reporting. Finally, we asked the 
participants to report their individual perceptions and experiences from the last four weeks, 
which may have given rise to inaccuracies due to recall bias.  
Our survey data was collected on one occasion, and we acknowledge that symptom 
experience, QoL and adherence may vary over time. Patient feedback confirmed this; some 
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respondents commented that administering the survey at a time closer to transplantation would 
yield different responses since certain ASI may be are more prevalent at that time. Other 
respondents acknowledged that they had various symptom experiences at different times post-
transplant. In our study, most of the respondents (61%) were transplanted at least six years ago, 
using this ‘snap-shot’ approach as we have, may have led to an under- or over-estimates of ASI 
occurrence. Future studies should examine the effect of time since transplant on over ASI 
occurrence in and aim for a more heterogeneous population.  
There was no control group in this study to identify differences in symptom experience 
between transplant recipients and non-transplant recipients. Consequently, we were unable to 
ascertain whether the reported symptoms are also experienced by the general population, and if 
in fact they are a consequence of transplantation. We included questions to ascertain the 
perceived cause of the adverse effects, however, since this area has been largely unexplored in 
previous research.  
Although the questionnaire consisted of three validated tools, its final formatting was not 
tested for validity and internal reliability. This may have resulted in problematic or unidentified 
issues such as ambiguity of some questions; however, consultation with experts and testing on 10 
lay people were done to minimize these problems. The questionnaire contained only one open-
text comment box at the end of the survey. For example, patient#21 wrote: “Hard to answer 
some of the questions, for example, some are not yes/no questions, and perhaps after the first 
section there should be a comments section.”  In the future, the addition of open-text comments 
boxes for each section would enable the respondents to elaborate in their feedback and enhance 
capturing respondent’s perceptions.  
Technical issues such as the survey not being iPad or mobile friendly, and other issues 
such as the malfunction of skip logic for some questions may have led to incomplete 
questionnaires. Some difficulties also occurred with survey distribution. Because the survey was 
sent through the CTA, there was no way to track undeliverable emails or incorrect email 
addresses. It was not possible to know which transplant recipients had received the survey emails 
and who had not. This information would have been useful in determining the true response rate 
and minimizing any potential non-response bias. Moreover, the CTA executive requested us to 
decrease the number of emails sent to their members, which may have affected our response rate. 
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Nevertheless, our response rate of 51% is comparable or better than to that of other electronic 
surveys.  
In this study the interrelationship between symptom experience, QoL and nonadherence 
to immunosuppressive medications were not explored. The objectives of this study were to 
identify relevant tools, develop a tool, pilot test it and perform descriptive analysis to 
characterize symptom experience, QoL and nonadherence in a sample of solid organ transplant 
recipients. Furthermore, as this was a pilot study to assess feasibility of a future study, studying 
the interrelationship is recommended as a target of future research. 
6.5 Conclusions 
To our knowledge this study was the first to explore patients’ perception on causal 
attribution and treatability of adverse symptoms, as well as assessing symptom experience, 
quality of life, and nonadherence to immunosuppressive medications collectively in a sample of 
solid organ transplant recipients. The intersection of perceived distress versus frequency revealed 
that higher prevalent symptoms are not necessarily the most distressing ones. In general, 
transplant recipients reported a good QoL and adherence to immunosuppressive medications, 
despite experiencing a high number of adverse symptoms. Future study should expand on the 
information generated from this pilot, extending this research into other settings with a more 




Appendix A: Advance Letter/Survey Invitation 
 Dear Member of the Canadian Transplant Association, 
Our names are Holly, Shirin and Jennifer and we are pharmacists who work and do 
research in transplantation. We are contacting you today to see if you might be interested in 
helping us with our latest study.   
As health care professionals working with transplant patients, we know that transplant 
medications may cause side effects that are bothersome or that may affect your daily activities.  
The purpose of this survey is to find out what side affects you as a transplant patient find most 
bothersome, how they affect your life, and your ability to take medications.   
We hope that the knowledge gained from this research will help us understand the things 
that we can do to help people take their anti-rejection medications, improve transplant care and 
have healthier transplant patients.  Your opinions and experiences as a transplant patient are very 
important in carrying out this project.  
We know that your time is valuable and limited, but we hope you will feel that this 
project is as important as we do.  By taking part in this survey you can make a difference in the 
care of transplant patients!  Completing the survey should take 30 to 45 minutes. Your answers 
in the survey will be anonymous and your decision to take part is voluntary. There is no risk to 
participation and your refusal to take part will not affect your transplant care in any way. 
As a token of our appreciation for your participation, we are offering a $10 Tim Horton’s 
gift card. If you would like to receive the gift card, we will need to collect your name and 
address, so that we can mail it to you.  After you have completed the survey you will be directed 
to an optional link to provide us with your mailing information. Your survey responses will not 
be linked to your personal information (so we will have no way of identifying your responses). 
To complete the survey, please go to the link below: 
Patient Survey on Side Effects of Transplant Medications 
If the link above does not work, try copying the link below into your web browser:  
https://redcap.usask.ca/redcap/surveys/?s=D8FNMTFNR7 
 
This survey is hosted by REDCap, a USA owned company and subject to US laws. As 
such the privacy of the information you provide may be subject to the laws of that jurisdiction. 
By participating in this survey you acknowledge and agree that although your answers will be 
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stored in Canada they may or may not receive the same level of privacy protection afforded by 
Canadian law. Your responses in the survey, however, will remain anonymous. 
By completing the survey, YOUR FREE AND INFORMED CONSENT IS IMPLIED 
and indicates that you understand the above conditions of participation in this study. 
The deadline for completing the survey is May 10, 2015.   
This research project has been approved on ethical grounds by the University of 
Saskatchewan Research Ethics Board.  Any questions regarding your rights as a participant may 
be addressed to that committee through the Research Ethics Office ethics.office@usask.ca (306) 
966-2975. Out of town participants may call toll free (888) 966-2975. If you have any questions 
about the project itself, you may contact Holly Mansell at (306) 966-1512 or 
holly.mansell@usask.ca. Results of the survey will be shared with the CTA membership either 
by email or by posting the results on the CTA website. 
 
We are grateful for your help and thank-you for being an important part of this project!  
 
Sincerely, 
Shirin Aladwin, BScPharm, MBA 
Pharmacist/Graduate Student 
University of Saskatchewan 
 
Holly Mansell, PharmD 
Transplant Pharmacist/Advisor 
University of Saskatchewan/Saskatchewan Transplant Program 
 
Jennifer Harrison, BScPharm, MSc 
Transplant Pharmacist/Project Co-lead 






Appendix B: First Reminder 
Dear Member of the Canadian Transplant Association, 
A week ago, you received an email inviting you to take part in a survey about transplant 
medications. The purpose of the survey is to learn more about your experiences with side effects 
of transplant medications so that we can manage them better. 
 If you have already completed the survey, we thank you very much for your help with 
this project! We apologize for sending you another email – since the survey is 
anonymous, our research team has no way of identifying which members have already 
completed the survey. 
 If you have not had a chance to complete the survey yet, we would still love to hear from 
you! To make this project a complete success we still need 120 additional respondents to 
complete the survey. If you have partially completed the survey, you still have the 
opportunity to complete it - unfortunately we can only use fully completed surveys. The 
survey will be open until May 10.  
To complete the survey, please go to the link below: 
Patient Survey on Side Effects of Transplant Medications 
If the link above does not work, try copying the link below into your web browser:  
https://redcap.usask.ca/redcap/surveys/?s=D8FNMTFNR7 
As a token of our appreciation for your participation, we are offering a $10 Tim Horton’s 
gift card.  If you would like to receive the gift card, we will need to collect your name and 
address, so that we can mail it to you.  After you have completed the survey you will be directed 
to an optional link to provide us with your mailing information. Your survey responses will not 
be linked to your personal information (so we will have no way of identifying your responses). 
This survey is hosted by REDCap, a USA owned company and subject to US laws. As 
such the privacy of the information you provide may be subject to the laws of that jurisdiction. 
By participating in this survey you acknowledge and agree that although your answers will be 
stored in Canada they may or may not receive the same level of privacy protection afforded by 
Canadian law. Your responses in the survey, however, will remain anonymous. 
By completing the survey, YOUR FREE AND INFORMED CONSENT IS IMPLIED 
and indicates that you understand the above conditions of participation in this study. 
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The deadline for completing the survey is May 10, 2015.   
 
This research project has been approved on ethical grounds by the University of 
Saskatchewan Research Ethics Board.  Any questions regarding your rights as a participant may 
be addressed to that committee through the Research Ethics Office ethics.office@usask.ca (306) 
966-2975. Out of town participants may call toll free (888) 966-2975. If you have any questions 
about the project itself, you may contact Holly Mansell at (306) 966-1512 or 
holly.mansell@usask.ca. Results of the survey will be shared with the CTA membership either 
by email or by posting the results on the CTA website. 
 
We are grateful for your help and thank-you for being an important part of this project!  
 
Sincerely, 
Shirin Aladwan, BScPharm, MBA 
Pharmacist/Graduate Student 
University of Saskatchewan 
 
Holly Mansell, PharmD 
Transplant Pharmacist/Advisor 
University of Saskatchewan/Saskatchewan Transplant Program 
 
Jennifer Harrison, BScPharm, MSc 
Transplant Pharmacist/Project Co-lead 











Appendix C: Final Reminder 
Dear Member of the Canadian Transplant Association, 
On behalf of the research team we want to send our sincere thanks for your help with our 
survey on side effects of transplant medications! We apologize for any technical inconvenience 
that you may have experienced, and that the survey cannot be completed on an ipad. We have 
noticed that a number of participants have started, but not yet completed the survey. Many of you 
are so close! We hope that you will consider answering a few more questions, as your input is 
truly important to us. This is the final email you will receive - the close date has been extended to 
May 24, 2015. 
 
Thanks again, 
Shirin, Holly and Jennifer. 
 
To complete the survey, please go to the link below: 
Patient Survey on Side Effects of Transplant Medications 
If the link above does not work, try copying the link below into your web browser:  
https://redcap.usask.ca/redcap/surveys/?s=D8FNMTFNR7 
As a token of our appreciation for your participation, we are offering a $10 Tim Horton’s 
gift card.  If you would like to receive the gift card, we will need to collect your name and 
address, so that we can mail it to you.  After you have completed the survey you will be directed 
to an optional link to provide us with your mailing information. Your survey responses will not 
be linked to your personal information (so we will have no way of identifying your responses). 
This survey is hosted by REDCap, a USA owned company and subject to US laws. As 
such the privacy of the information you provide may be subject to the laws of that jurisdiction. 
By participating in this survey you acknowledge and agree that although your answers will be 
stored in Canada they may or may not receive the same level of privacy protection afforded by 
Canadian law. Your responses in the survey, however, will remain anonymous. 
 
By completing the survey, YOUR FREE AND INFORMED CONSENT IS IMPLIED 




This research project has been approved on ethical grounds by the University of 
Saskatchewan Research Ethics Board.  Any questions regarding your rights as a participant may 
be addressed to that committee through the Research Ethics Office ethics.office@usask.ca (306) 
966-2975. Out of town participants may call toll free (888) 966-2975. If you have any questions 
about the project itself, you may contact Holly Mansell at (306) 966-1512 or 
holly.mansell@usask.ca. Results of the survey will be shared with the CTA membership either 
by email or by posting the results on the CTA website. 
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